

KANGJI 康基

康基医疗控股有限公司
Kangji Medical Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

Stock Code 股份代號：9997

2024
INTERIM REPORT
中期報告



Contents

目錄

2	Corporate Information	公司資料
4	Financial Highlights	財務摘要
5	Management Discussion and Analysis	管理層討論與分析
22	Corporate Governance and Other Information	企業管治及其他資料
33	Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	中期簡明綜合損益及其他全面收益表
35	Interim Condensed Consolidated Statement of Financial Position	中期簡明綜合財務狀況表
37	Interim Condensed Consolidated Statement of Changes in Equity	中期簡明綜合權益變動表
39	Interim Condensed Consolidated Statement of Cash Flows	中期簡明綜合現金流量表
42	Notes to the Interim Condensed Consolidated Financial Information	中期簡明綜合財務資料附註
66	Definitions	釋義



Corporate Information

公司資料

BOARD OF DIRECTORS

Executive Directors

Mr. ZHONG Ming (*Chairman*)
Ms. SHENTU Yinguang
Mr. YIN Zixin

Non-executive Director

Ms. CAI Li

Independent Non-executive Directors

Mr. JIANG Feng
Mr. GUO Jian
Mr. CHEN Weibo

AUDIT COMMITTEE

Mr. CHEN Weibo (*Chairman*)
Mr. JIANG Feng
Ms. CAI Li

REMUNERATION COMMITTEE

Mr. CHEN Weibo (*Chairman*)
Ms. SHENTU Yinguang
Mr. GUO Jian

NOMINATION COMMITTEE

Mr. ZHONG Ming (*Chairman*)
Mr. JIANG Feng
Mr. GUO Jian

ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE

Mr. ZHONG Ming (*Chairman*)
Ms. SHENTU Yinguang
Mr. YIN Zixin

COMPANY SECRETARY

Mr. WAN Siu Keung

AUTHORIZED REPRESENTATIVES

Mr. ZHONG Ming
Mr. YIN Zixin

AUDITOR

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

董事會

執行董事

鍾鳴先生 (*董事長*)
申屠銀光女士
尹自鑫先生

非執行董事

蔡俐女士

獨立非執行董事

姜峰先生
郭建先生
陳衛波先生

審核委員會

陳衛波先生 (*主席*)
姜峰先生
蔡俐女士

薪酬委員會

陳衛波先生 (*主席*)
申屠銀光女士
郭建先生

提名委員會

鍾鳴先生 (*主席*)
姜峰先生
郭建先生

環境、社會及管治委員會

鍾鳴先生 (*主席*)
申屠銀光女士
尹自鑫先生

公司秘書

溫兆強先生

授權代表

鍾鳴先生
尹自鑫先生

核數師

安永會計師事務所
執業會計師
註冊公眾利益實體核數師
香港
鰂魚涌
英皇道979號
太古坊一座27樓

Corporate Information

公司資料

REGISTERED OFFICE

Appleby Global Services (Cayman) Limited
71 Fort Street
P.O. Box 500
George Town
Grand Cayman KY1-1106
Cayman Islands

CORPORATE HEADQUARTERS

No. 1668 Chunjiang East Road
Tonglu Economic Development Zone
Hangzhou
Zhejiang Province
PRC

HONG KONG LEGAL ADVISER

Cleary Gottlieb Steen & Hamilton (Hong Kong)
37/F, Hysan Place
500 Hennessy Road
Causeway Bay
Hong Kong

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Flat 1007B, 10/F, Harbour Crystal Centre
100 Granville Road, Kowloon
Hong Kong

HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

INVESTOR RELATIONS

T: +86 571 69900020
E: ir@kangji.com

WEBSITE

www.kangjimedical.com

STOCK CODE

9997

註冊辦事處

Appleby Global Services (Cayman) Limited
71 Fort Street
P. O. Box 500
George Town
Grand Cayman KY1-1106
Cayman Islands

公司總部

中國
浙江省
杭州市
桐廬經濟開發區
春江東路1668號

香港法律顧問

佳利(香港)律師事務所
香港
銅鑼灣
軒尼詩道500號
希慎廣場37樓

香港主要營業地點

香港九龍
加連威老道100號
港晶中心10樓1007B室

香港股份過戶登記處

香港中央證券登記有限公司
香港
灣仔
皇后大道東183號
合和中心
17樓1712-1716室

投資者關係

電話 : +86 571 69900020
電郵 : ir@kangji.com

網址

www.kangjimedical.com

股份代號

9997

Financial Highlights

財務摘要

The financial highlights of the Group for the Reporting Period together with the comparative figures for the corresponding period in the four financial periods, as extracted from/calculated based on the unaudited financial information and financial statements are set out as follows:

本集團於報告期內的財務摘要連同最近四個財政期間的同期比較數字(摘錄自未經審核財務資料及財務報表/根據該等資料及報表計算得出)載列如下:

		Six months ended June 30, 截至6月30日止六個月				
		2024 2024年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 2021年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 2020年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Revenue	收入	458,413	403,589	332,321	318,124	212,587
Gross profit	毛利	363,123	321,755	265,712	261,227	177,634
Profit for the period	期內利潤	275,686	229,297	153,497	199,358	89,596
Profit attributable to owners of the parent	母公司擁有人應佔利潤	285,847	255,461	157,713	199,358	80,742
Non-HKFRS adjusted net profit attributable to owners of the parent*	母公司擁有人應佔非《香港財務報告準則》經調整純利	274,873	237,185	215,320	201,195	124,544
Earnings per share	每股盈利					
- Basic (RMB)	- 基本 (人民幣)	24.39 cents	21.83 cents	12.95 cents	16.27 cents	11.92 cents
		24.39分	21.83分	12.95分	16.27分	11.92分
- Diluted (RMB)	- 攤薄 (人民幣)	24.39 cents	21.73 cents	12.95 cents	16.14 cents	11.82 cents
		24.39分	21.73分	12.95分	16.14分	11.82分

* For details, please see section headed "Management Discussion and Analysis – Non-HKFRS Measures"

* 詳情請參閱「管理層討論與分析—非《香港財務報告準則》計量」一節。

For the Reporting Period, the Company realized revenue of RMB458.4 million, representing an increase of 13.6% as compared to the corresponding period in 2023. The Group's increase in sales was mainly attributable to the increase in sales of disposable products.

於報告期內，本公司實現人民幣458.4百萬元收入，相較2023年同期增長13.6%。本集團銷售增加主要歸因於一次性產品的銷售增加。

The Group's net profit attributable to owners of the parent for the Reporting Period increased by 11.9% from RMB255.5 million in 2023 to RMB285.8 million in 2024. The increase was mainly due to the increase in revenue and other income and gains. The Group's non-HKFRS adjusted net profit attributable to owners of the parent for the Reporting Period increased by 15.9% from RMB237.2 million in 2023 to RMB274.9 million in 2024.

本集團於報告期內母公司擁有人應佔純利由2023年的人民幣255.5百萬元增加11.9%至2024年的人民幣285.8百萬元。有關增加的主要原因為收入及其他收入及收益增加。本集團於報告期內母公司擁有人應佔非《香港財務報告準則》經調整純利由2023年的人民幣237.2百萬元增加15.9%至2024年的人民幣274.9百萬元。

The Board did not recommend the payment of any interim dividend for the six months ended June 30, 2024.

董事會不建議支付截至2024年6月30日止六個月的任何中期股息。

Management Discussion and Analysis

管理層討論與分析

OUR MISSION

Our mission is to enable physicians and improve health and wellness of patients through providing high performing and accessible products and services.

BUSINESS OVERVIEW AND OUTLOOK

The Group is a leading medical device manufacturer in China, offering a diverse range of products including medical equipment, instruments, and accessories focused on minimally invasive surgery. During the Reporting Period, the Group increased its equity interest in Weijing Medical from 35% to 37%. Through its holding of equity interest in Weijing Medical, the Group holds a platform for laparoscopic surgical robots. The Group can leverage its extensive sales and distribution resources, as well as its capabilities in manufacturing, conducting clinical trials, and regulatory affairs in China, to support the development and deployment of the surgical robots on this platform.

As China's economic activity recovered from the pandemic in the first half of 2023, patient traffic and surgery volumes increased significantly, which established an elevated baseline for the Group's performance in the first half of 2024. The anti-corruption campaigns over the healthcare industry launched in the second half of 2023 have gradually normalized, they will still bring short-term impacts on the medical device industry. Despite these, the Group achieved a growth in its domestic revenue for the Reporting Period, which was primarily driven by increased sales of major disposable product categories, such as disposable trocars, ligation clips, disposable electrocoagulation forceps and other disposable products, as well as strong year-over-year growth in sales of some new products, such as ultrasonic scalpels and staplers.

On VBP, during the Reporting Period, the Beijing-Tianjin-Hebei 3+N alliance had commenced the implementation of VBPs for staplers and ultrasonic scalpels gradually from February 2024 onwards. Besides, the Group won bid for the VBP of ultrasonic scalpels under the Sichuan-Chongqing alliance. We do not expect any change to the distributor model of such products and are currently awaiting notification on the implementation timeline. Notably, a new VBP of hemostatic tissue ligation clips was officially announced in July, which is a Fujian-led nationwide alliance procurement. This procurement encompasses a wide range of hemostatic tissue ligation clip products, and is a nationwide alliance procurement initiative led at the provincial level with a broad geographical coverage. We have a comprehensive portfolio of hemostatic tissue ligation clip products, including polymer ligation clips, titanium clips, absorbable clips, multi-fire ligation clips, and multi-fire titanium clips. Among these, the multi-fire ligation clips, a novel product approved during the Reporting Period, met the product criteria for inclusion in this nationwide alliance procurement. We foresee that the national-level VBP will facilitate accelerated penetration of our products into the end-market, while also supporting import substitution and enabling us to gain bigger market share.

我們的使命

我們的使命是透過提供優質及便捷的產品及服務協助醫生並改善患者的健康狀況。

業務回顧及未來展望

本集團是中國一家領先醫療器械製造商，提供多元化產品，包括專注於微創手術的醫療設備、器械和耗材。於報告期內，本集團在唯精醫療持有的股權由35%增加至37%。本集團透過持有唯精醫療股權，擁有腹腔鏡手術機器人平台。本集團可利用其豐富的銷售及經銷資源，以及在中國的製造、臨床試驗及監管事務能力，支援該平台上手術機器人的開發及部署。

2023年上半年中國經濟活動從疫情中復甦，病人流量及手術量大幅增加，為本集團於2024年上半年的表現基準建立較高基數。2023年下半年開展的醫療行業反腐行動逐漸常態化，短期內對醫療器械行業仍會有影響。儘管如此，於報告期內，本集團的國內收入仍實現增長，主要由核心一次性產品類別（例如一次性套管穿刺器、結紮夾、一次性電凝鉗及其他一次性產品）的銷售增加以及部分新產品，如超聲切割止血刀及吻合器的銷售按年增長強勁所帶動。

就集採而言，於報告期內，京津冀3+N聯盟已自2024年2月起逐步開始執行集採吻合器及超聲切割止血刀。而且，本集團中標川渝聯盟下的超聲切割止血刀集採。我們預期該等產品經銷商模式不會有任何變動，且目前正在等待執行時間表的通知。值得注意的是，新的止血組織結紮夾集採已於7月正式公佈，為福建省牽頭的全國聯盟採購。該採購涉及多種止血組織結紮夾產品，為由省份牽頭、地域覆蓋廣泛的全國聯盟集中採購措施。我們擁有全面的止血組織結紮夾產品組合，包括高分子結紮夾、鈦夾、可吸收夾、連發結紮夾及連發鈦夾。當中，在報告期內獲批的新產品連發結紮夾符合該全國聯盟採購的產品標準。我們預計，國家級集採將有助於加快我們的產品滲透至終端市場，同時亦支持進口替代，令我們獲得更大市場份額。

Management Discussion and Analysis

管理層討論與分析

Outside of China, we continued to record growth for exports. Both our customer base and geographical reach continued to expand in the first half of 2024. We believe overseas markets present substantial growth opportunities, particularly in regions previously underserved or unexplored. Throughout the Reporting Period, we focused on enhancing our overseas distributor management by adjusting some of our distributors and refining our customer portfolio. Additionally, shipping schedule issues in South America during the first half of 2024 contributed to a set of factors influencing our export business growth during this Reporting Period. For the six months ended June 30, 2024, the Group achieved an export sales of RMB40.2 million, representing a 2.7% growth from the corresponding period of the previous year.

The growth was primarily attributable to increased sales in the European market. We continued to invest heavily in overseas product registration and approval processes. This included registering our existing products in more countries and regions, as well as accelerating the CE certification applications for some of our promising new products. For example, we obtained 510(k) clearance for a disposable trocar in the United States, and secured new registrations for our visualization trocars and single-port trocars in Panama during the Reporting Period. We have also actively participated in and prepared for more industry conferences and international academic promotion events. During the Reporting Period, the Group added 11 new overseas product registrations, mainly in Central and South America as well as Southeast Asia, partly through partnerships with overseas original equipment manufacturer (OEM) customers or distributors.

For the six months ended June 30, 2024, the Group achieved a total revenue of RMB458.4 million, representing a 13.6% increase from the corresponding period of the previous year. The growth in revenue was mainly attributable to the increase in sales of disposable trocars, ligation clips, disposable electrocoagulation forceps, ultrasonic scalpels, staplers and other disposable products. The Group's net profit attributable to owners of the parent for the six months ended June 30, 2024 has increased by 11.9% from RMB255.5 million for the corresponding period in 2023 to RMB285.8 million in the Reporting Period. The increase was mainly attributable to the increases in revenue and other income and gains. The Group's adjusted net profit attributable to owners of the parent for the Reporting Period, which excludes fair value gains on financial assets at fair value through profit or loss, share-based payment expense, foreign exchange difference, investment income from short-term financial products and gain on deconsolidation of Weijing Medical, has increased by 15.9% from RMB237.2 million for the corresponding period in 2023 to RMB274.9 million in the Reporting Period.

於國外市場，我們的出口繼續錄得增長。於2024年上半年，我們的客戶基礎及地理覆蓋範圍持續擴大。我們相信海外市場存在大量增長機會，特別是以往未充分服務或未開發的地區。於整個報告期內，我們重點加強海外經銷商管理，調整了部分經銷商，優化了客戶結構。此外，於2024年上半年，南美洲的運輸期問題亦對我們於報告期內的出口業務增長產生了若干影響因素。截至2024年6月30日止六個月，本集團實現出口銷售人民幣40.2百萬元，較去年同期增長2.7%。

有關增長主要歸因於歐洲市場銷售增加。我們繼續大力投資海外產品註冊及審批流程。其包括在更多國家及地區註冊我們的現有產品，以及加快申請部分有前景的新產品的CE認證。例如，於報告期內，我們在美國就一次性套管穿刺器取得510(k)許可，並在巴拿馬就可視化套管穿刺器及單孔套管穿刺器辦理新註冊。我們亦積極參與及籌備更多行業會議及國際學術推廣活動。於報告期內，本集團新增11項海外產品註冊，主要在中南美洲及東南亞，部分透過海外原設備製造商(OEM)客戶合作或經銷商進行註冊。

截至2024年6月30日止六個月，本集團實現總收入人民幣458.4百萬元，較去年同期增長13.6%。收入增長主要歸因於一次性套管穿刺器、結紮夾、一次性電凝鉗、超聲切割止血刀、吻合器及其他一次性產品銷售增加。本集團截至2024年6月30日止六個月的母公司擁有人應佔純利由2023年同期的人民幣255.5百萬元增加11.9%至報告期內的人民幣285.8百萬元。有關增加主要歸因於收入及其他收入及收益增加。本集團於報告期內的母公司擁有人應佔經調整純利（不計及以公允價值計量且其變動計入當期損益的金融資產的公允價值收益、以股份為基礎的付款開支、匯兌差額、短期金融產品的投資收益以及取消合併唯精醫療的收益）由2023年同期的人民幣237.2百萬元增加15.9%至報告期內的人民幣274.9百萬元。

Management Discussion and Analysis

管理層討論與分析

Research and Development

During the Reporting Period, the Group added 12 new product registrations in China, excluding the renewal of existing product registrations. As of June 30, 2024, the Group had a total of 104 domestic National Medical Products Administration (NMPA) product registrations, including 14 for Class III medical devices, 55 for Class II medical devices, and 35 for Class I medical devices. In the Reporting Period, the Group also obtained 20 new patents in China, whereas Weijing Medical obtained 50 new patents on a standalone basis.

The Group continued to increase its R&D investment, with a firm focus on the field of minimally invasive surgery. Committed to providing surgeons with comprehensive minimally invasive surgical solutions, we are focusing our R&D efforts on projects that offer promising market potential, lower risk profiles, and enable us to enhance our existing minimally invasive surgical product portfolio. This strategy includes both the refinement and iteration of our existing products, as well as driving innovation through the synergy of clinical practice and engineering, guided by a clinically-oriented approach.

During the Reporting Period, the Group's product portfolio continued to expand and evolve, with breakthroughs particularly in our closure devices. We obtained an approval for an absorbable knotless suture, a Class III medical device. This advanced suture allows for suturing without the need for knot-tying, thereby improving the efficiency of surgical suturing and simplifying complex procedures. The product has outstanding biocompatibility and can be gradually absorbed by the body after implantation. Absorbable knotless sutures were introduced relatively recent in the Chinese market, and their market penetration remains at a nascent stage, with imported brands currently dominating the market. We expect there will be significant growth opportunities for domestic products in the future. Another closure device that was approved in the first half of the year is the multi-fire ligation clips, another Class III medical device. This product allows for continuous vessel and tissue ligation, avoiding the need for repeated entry and exit of the abdominal cavity during laparoscopic surgery, thereby improving surgical efficiency. Additionally, during the Reporting Period, the Group added two important products to the comprehensive solution for hysteroscopic procedure, including a rigid hysteroscope and a disposable electronic hysteroscope, providing surgeons with more tools for gynecological examinations.

In June 2024, a new R&D building at the Group's Hangzhou headquarters became operational. This building along with other enhanced facilities, strengthens the foundation for the Group's ongoing innovation and product development. The improved working environment in this building is expected to bolster R&D capabilities and aid in attracting top-tier research talent. At the same time, the expanded R&D space allows for more flexible configuration of specialized laboratories, such as the addition of equipment for IEC and high-frequency signal testing. Furthermore, the Group has also built a new animal testing center, which can accelerate product development efficiency and improve R&D quality.

研究及開發

於報告期內，本集團於中國新增12項新產品註冊（不計及現有產品註冊續新）。截至2024年6月30日，本集團於中國合共有104項產品獲得中國國家藥品監督管理局（NMPA）註冊，包括14項第三類醫療器械、55項第二類醫療器械以及35項第一類醫療器械。於報告期內，本集團亦於中國取得20項新專利，而唯精醫療則獨立取得50項新專利。

本集團持續加大研發投資，重點為微創手術領域。我們致力於為外科醫生提供全面的微創手術解決方案，將研發工作重點放在具有良好市場潛力、風險較低，且有助我們增強現有微創手術產品組合的產品。該策略包括優化及迭代升級現有產品，以及以臨床為導向，透過醫工結合推動創新。

於報告期內，本集團的產品組合持續擴大和發展，尤其是在閉合類產品方面取得突破。我們就一款可吸收免打結縫合線（第三類醫療器械）取得批准。該先進縫合線無需打結即可縫合，從而提高手術縫合的效率及簡化複雜手術。該產品的生物相容性出色，植入後可逐漸被人體吸收。可吸收免打結縫合線在中國市場的推出時間相對較短，其市場滲透率仍處於初期階段，目前進口品牌佔據市場主導地位。我們預期，未來國內產品將有龐大增長機會。上半年獲批准的另一款閉合類產品為連發結紮夾，亦為第三類醫療器械。該產品可連續結紮血管及組織，避免於腹腔鏡手術時重複進出腹腔，從而提高手術效率。此外，於報告期內，本集團在宮腔鏡手術綜合解決方案中加入兩款重要產品，包括硬性宮腔鏡及一次性電子宮腔鏡，為外科醫生提供更多婦科檢查工具選項。

於2024年6月，本集團杭州總部新研發大樓投入使用。該大樓加上其他經改進設施，鞏固本集團持續創新及產品開發的基礎。該大樓經提升後的工作環境預期將會增強研發能力並有助於吸引頂尖研究人才。同時，經擴大的研發空間可以更靈活地配置專門實驗室，例如增加IEC及高頻訊號測試設備。此外，本集團亦已建設新的動物實驗中心，可加快產品開發效率，提升研發品質。

Management Discussion and Analysis

管理層討論與分析

In terms of Weijing Medical, the 4-arm surgical robotic system has completed multi-specialty human clinical trials as of March 2024 and the registration application has been submitted. It is expected to obtain regulatory approvals around the end of 2024. The single-port surgical robotic system has completed product design finalization and is currently undergoing testing and validation. It is expected to complete type inspection and animal testing in the second half of the year, with the goal of starting human clinical trials by the end of 2024. In 2024, the Group and Weijing Medical jointly participated in multiple academic conferences and industry exhibitions, such as the 2024 Academic Annual Meeting of the Chinese Society of Pancreatology in late June in Hangzhou, and the 2024 Annual Conference of the Chinese Medical Doctor Association Surgery Branch in mid-July in Shanghai. Weijing Medical also plans to actively participate in more academic and industry conferences in the second half of the year. Furthermore, Weijing Medical has begun to collaborate with leading regional hospitals to provide standardized training on the use of its robotic systems, facilitating the exchange of laparoscopic surgical techniques and promoting the delivery of high-quality medical resources to the regional healthcare facilities.

Sales and Distribution

We have been continuously promoting the application of new and advanced surgical techniques, organizing a series of single-port surgery video competitions throughout the first half of the year, encouraging doctors to actively explore single-port minimally invasive techniques and driving progress in this field. Meanwhile, we have also launched the promotion of surgical robots, with Kangji and Weijing Medical jointly participating in multiple industry exhibitions and forums. We have organized academic seminars on the hot topic of single-port surgery for multiple specialties, inviting experts to engage in in-depth discussions and share their experiences. In addition, there have been other academic activities for specialties such as hepatobiliary surgery and urology, including live surgeries, salons, and lecture tours. Looking ahead to the second half of the year, we will launch a training program related to single-use hysteroscope, providing systematic technical training to help more doctors master this advanced technique.

In the first half of 2024, we also carried out a series of optimizations in our marketing management and distributor relationships. Through measures such as strengthening communication, improving team collaboration, and enhancing product training, we improved distributor satisfaction and sales capabilities, laying a solid foundation for achieving our annual goals. We engaged in in-depth and continuous interaction with key distributors, strengthening mutual understanding and communication. We also optimized the division of our market team by region and product line, improving market responsiveness and service levels. We continuously enhanced our training programs for new products and major products, ensuring distributors thoroughly understand product features and usage techniques, and enabling them to provide better support to end customers.

就唯精醫療而言，截至2024年3月，四臂手術機器人系統已完成多科室人體臨床試驗，並已提交註冊申請。預期將於2024年年底前後取得監管部門批准。單孔手術機器人系統已完成產品設計定型，目前正在進行測試及驗證。預期將於下半年完成型式檢驗及動物試驗，目標為於2024年年底展開人體臨床試驗。於2024年，本集團及唯精醫療已聯合參加多次學術會議及行業展覽，例如6月下旬於杭州舉行的中國胰腺病學會2024年學術年會以及7月中旬於上海舉行的中國醫師協會外科分會2024年年會。唯精醫療亦計劃於下半年積極參與更多的學術及行業會議。此外，唯精醫療已開始與領先的地區醫院合作，提供其機器人系統使用的規範化培訓，促進腹腔鏡手術技術交流，並推動優質醫療資源下沉至地區醫療機構。

銷售及經銷

我們一直不斷地推廣新的先進外科技術的應用，貫穿整個上半年舉辦了一系列單孔手術視頻比賽，鼓勵醫生積極探索單孔微創技術，推動該領域進步。同時，我們亦展開手術機器人推廣，康基及唯精醫療聯合參與多個行業展覽及論壇。我們針對單孔手術熱門話題，就多個專科舉辦學術研討會，邀請專家參與深入討論，分享經驗。此外，肝膽外科及泌尿外科等專科亦開展其他學術活動，包括手術直播、沙龍及巡迴講座。展望下半年，我們將推出一一次性宮腔鏡相關培訓項目，提供系統性技術培訓，幫助更多醫生掌握該先進技術。

於2024年上半年，我們亦在市場推廣管理及經銷商關係方面進行一系列優化。我們透過加強溝通、提升團隊協作、強化產品培訓等措施，提升經銷商滿意度及銷售能力，為實現年度目標奠定堅實基礎。我們與重點經銷商深入持續互動，加強互相了解及溝通。我們亦按區域及產品線優化市場團隊劃分，並提高了市場響應能力及服務水平。我們持續加強新產品及主要產品培訓計劃，確保經銷商充分了解產品特性及使用技巧，令彼等可為終端客戶提供更佳支援。

Management Discussion and Analysis

管理層討論與分析

Forward Outlook

Looking ahead, the domestic market still harbours huge potential, and the Group is confident that it will maintain its leading foothold in minimally invasive surgical instruments and consumables market. The Group is determined to seize the development opportunities brought to the industry by VBP, the increasing penetration rate of minimally invasive surgery and China's aging population. We are committed to expanding and refining our product portfolio to comprehensively address surgeons' evolving needs, offering increasingly complete minimally invasive surgical solutions. Additionally, we have already established a strong brand presence in the domestic market, with the quality of our core products on par with imported offerings. Going forward, we will bolster our overseas marketing network to capture the broader long-term market growth opportunities. By implementing these strategic measures, we will solidify and enhance our market position in the minimally invasive surgery field, staying attuned to the ever-rising clinical demands and driving the Company's long-term sustainable growth.

FINANCIAL REVIEW

The following discussions are based on the financial information and notes set out in other sections of this report and should be read in conjunction with them:

Revenue

未來展望

展望未來，國內市場仍蘊藏著巨大的潛力，本集團有信心仍將在微創手術器械及耗材市場保持領先地位。本集團將緊抓集採、微創手術滲透率提升及中國人口老齡化給行業所帶來的發展機遇。我們將致力於擴大及完善我們的產品組合，全面地滿足外科醫生不斷變化的需要，提供日益完善的微創手術解決方案。此外，我們已在國內市場建立強大的品牌影響力，核心產品的品質與進口產品相當。日後，我們將加強海外市場推廣網絡，把握更多長期市場增長機會。透過實施該等策略措施，我們將鞏固並提升我們於微創手術領域的市場地位，適應不斷提升的臨床需求，推動本公司的長期可持續增長。

財務回顧

以下討論乃基於本報告其他章節所載財務資料及附註，並應與之一併閱讀：

收入

Six months ended June 30,
截至6月30日止六個月

		2024 2024年 RMB' 000 人民幣千元 (Unaudited) (未經審核)	2023 2023年 RMB' 000 人民幣千元 (Unaudited) (未經審核)	Changes 變動 %
Disposable products	一次性產品			
Disposable trocars	一次性套管穿刺器	191,702	169,856	12.9
Ligation clips	結紮夾	103,835	99,404	4.5
Disposable electrocoagulation forceps	一次性電凝鉗	67,041	51,505	30.2
Ultrasonic scalpels	超聲切割止血刀	23,737	12,479	90.2
Staplers	吻合器	3,708	305	1,115.7
Other disposable products ⁽¹⁾	其他一次性產品 ⁽¹⁾	19,118	8,471	125.7
Sub-total	小計	409,141	342,020	19.6
Reusable products	重複性產品			
4K endoscopic camera systems	4K內窺鏡攝像系統	13,001	17,888	(27.3)
Other reusable products ⁽²⁾	其他重複性產品 ⁽²⁾	36,271	43,681	(17.0)
Sub-total	小計	49,272	61,569	(20.0)
Total	總計	458,413	403,589	13.6

Management Discussion and Analysis

管理層討論與分析

Notes:

- (1) Other disposable products primarily include, among others, disposable suction and irrigation sets and retrieval bags.
- (2) Other reusable products primarily include reusable trocars and reusable forceps.

The Group's revenue amounted to RMB458.4 million for the six months ended June 30, 2024, representing an increase of 13.6% as compared to RMB403.6 million for the corresponding period in 2023. The increase in revenue was primarily attributable to the increase in sales of disposable products including disposable trocars, ligation clips, disposable electrocoagulation forceps, ultrasonic scalpels, staplers and other disposable products.

Disposable Products

The Group's disposable products include disposable trocars, ligation clips, disposable electrocoagulation forceps, ultrasonic scalpels, staplers and other disposable products. Disposable products recorded revenue of RMB409.1 million for the Reporting Period, representing an increase of 19.6% as compared to RMB342.0 million for the corresponding period in 2023. Such increase was attributable to the better growth of the Group's main disposable products including disposable trocars, ligation clips, electrocoagulation forceps, ultrasonic scalpels and staplers. During the Reporting Period, sales of disposable products accounted for 89.3% of the Group's total revenue as compared to 84.7% for the corresponding period in 2023.

Disposable trocars recorded revenue of RMB191.7 million for the Reporting Period, representing an increase of 12.9% as compared with RMB169.9 million for the corresponding period in 2023. Disposable trocars accounted for approximately 41.8% of the Group's total revenue during the Reporting Period as compared to approximately 42.1% for the corresponding period in 2023. In particular, sales of single-site trocars continued to exhibit high growth in the first half of 2024. During the Reporting Period, sales of disposable trocars attributable to VBP regions including Shandong, Fujian, Hunan, Hebei and Guangdong provinces recorded better growth in the first half of 2024.

Ligation clips recorded revenue of RMB103.8 million for the Reporting Period, representing an increase of 4.5% as compared with RMB99.4 million for the corresponding period in 2023. Ligation clips accounted for approximately 22.7% of the Group's total revenue during the Reporting Period. Sales of ligation clips exhibited slight growth as influenced by the forthcoming Fujian-led nationwide VBP where the bidding process will be concluded in the third quarter of 2024. We are confident that the outcome of such nationwide VBP of ligation clips will be favourable to the Group, and thus boosting the certainty of its future sales growth of the Group.

附註：

- (1) 其他一次性產品主要包括(其中包括)一次性沖洗吸引器及取物袋等。
- (2) 其他重複性產品主要包括重複性套管穿刺器及重複性鉗類。

截至2024年6月30日止六個月，本集團的收入為人民幣458.4百萬元，較2023年同期的人民幣403.6百萬元增加13.6%。收入增長主要由於一次性產品的銷售增加，包括一次性套管穿刺器、結紮夾、一次性電凝鉗、超聲切割止血刀、吻合器及其他一次性產品。

一次性產品

本集團的一次性產品包括一次性套管穿刺器、結紮夾、一次性電凝鉗、超聲切割止血刀、吻合器及其他一次性產品。一次性產品於報告期內錄得收入人民幣409.1百萬元，較2023年同期的人民幣342.0百萬元增加19.6%。有關增加的原因為一次性套管穿刺器、結紮夾、電凝鉗、超聲切割止血刀、吻合器等本集團的主要一次性產品銷售的增長。於報告期內，一次性產品銷售額佔本集團總收入的89.3%，而2023年同期為84.7%。

於報告期內，一次性套管穿刺器錄得收入人民幣191.7百萬元，較2023年同期的人民幣169.9百萬元增加12.9%。於報告期內，一次性套管穿刺器佔本集團總收入約41.8%，而2023年同期則為約42.1%。具體而言，單孔套管穿刺器的銷售於2024年上半年持續呈現高增長。於報告期內，集採地區(包括山東、福建、湖南、河北及廣東省)應佔的一次性套管穿刺器銷售於2024年上半年錄得較好增長。

於報告期內，結紮夾錄得收入人民幣103.8百萬元，較2023年同期的人民幣99.4百萬元增加4.5%。於報告期內，結紮夾佔本集團總收入約22.7%。受即將舉行的福建省牽頭的全國集採影響(其招標過程將於2024年第三季度結束)，結紮夾的銷售呈現輕微增長。我們有信心，在此次結紮夾的國家聯採中取得的成果對本集團有所裨益，進而增強本集團銷售該類產品的未來增長確定性。

Management Discussion and Analysis

管理層討論與分析

Disposable electrocoagulation forceps recorded revenue of RMB67.0 million for the Reporting Period, which accounted for approximately 14.6% of the Group's total revenue for the Reporting Period as compared to 12.8% for the corresponding period in 2023. Disposable electrocoagulation forceps continued to experience high growth in demand and recorded high sales growth of 30.2% for the Reporting Period. As the use of disposable electrocoagulation forceps in minimally invasive surgery is still at a lower level, we consider that disposable electrocoagulation forceps are still exposed to better sales growth potential.

Sales of the Group's newer disposable products such as ultrasonic scalpels and staplers were boosted by the effort in strengthening market development and seizing the demand from import substitution and VBPs. During the Reporting Period, sales of ultrasonic scalpels amounted to RMB23.7 million, representing an increase of 90.2% as compared to RMB12.5 million for the corresponding period in 2023.

Reusable Products

Reusable products recorded revenue of RMB49.3 million for the Reporting Period, representing a decrease of 20.0% as compared with RMB61.6 million for the corresponding period in 2023. Such decrease was mainly due to the cyclical purchasing needs of 4K endoscopic camera systems and reusable forceps.

Sales Channel

Revenue from domestic market for the Reporting Period increased by 14.7% as compared to that of 2023. The Group's business models in domestic market include distributor model and non-distributor model (logistics partners + academic promotion), which is mainly used in the VBP provinces of disposable trocars.

For overseas markets, the Group's customers mainly include overseas ODM customers and overseas distributors. Revenue from overseas markets was approximately RMB40.2 million for the six months ended June 30, 2024, representing an increase of 2.7% from the corresponding period in 2023. Growth of export sales was moderate during the Reporting Period due to the Group was expanding its customer bases in Asia and Europe as well as consolidating its market presence in the South America. Revenue from overseas markets accounted for 8.8% of the Group's total revenue for the Reporting Period as compared to 9.7% for the corresponding period in 2023.

於報告期內，一次性電凝鉗錄得收入人民幣67.0百萬元，佔報告期內本集團總收入約14.6%，而2023年同期則為12.8%。於報告期內，對一次性電凝鉗的需求持續高增長並錄得高銷售增幅30.2%。由於一次性電凝鉗在微創手術中的使用率仍然較低，我們認為一次性電凝鉗仍具有較高銷售增長潛力。

本集團加強市場發展力度，把握進口替代及集採需求，帶動超聲切割止血刀及吻合器等新型一次性產品銷售增長。於報告期內，超聲切割止血刀的銷售額為人民幣23.7百萬元，較2023年同期的人民幣12.5百萬元增加90.2%。

重複性產品

於報告期內，重複性產品錄得收入人民幣49.3百萬元，較2023年同期的人民幣61.6百萬元減少20.0%。有關下降的主要原因為4K內窺鏡攝像系統及重複性鉗類的週期性採購需求。

銷售渠道

與2023年相比，報告期內國內市場的收入增加14.7%。本集團在國內市場的業務模式包括經銷商模式及非經銷商模式（物流夥伴+學術推廣），後者主要在集採一次性套管穿刺器的省份實施。

就海外市場而言，本集團的客戶主要包括海外ODM客戶及海外經銷商。截至2024年6月30日止六個月，海外市場收入約為人民幣40.2百萬元，較2023年同期增加2.7%。於報告期內，出口銷售錄得適度增長，原因為本集團正在擴大亞洲及歐洲國家的客戶基礎以及鞏固其於南美洲的市場份額。於報告期內，來自海外市場的收入佔本集團總收入的8.8%，而2023年同期則為9.7%。

Management Discussion and Analysis

管理層討論與分析

The following table sets forth the Group's revenue by geographic market and sales channel for the periods indicated:

下表載列於所示期間本集團按地域市場及銷售渠道劃分的收入：

		Six months ended June 30, 截至6月30日止六個月		
		2024 2024年 RMB' 000 人民幣千元 (Unaudited) (未經審核)	2023 2023年 RMB' 000 人民幣千元 (Unaudited) (未經審核)	Changes 變動 %
Domestic	國內			
- Distributors	- 經銷商	376,093	333,143	12.9
- Hospitals and other customers ⁽¹⁾	- 醫院及其他客戶 ⁽¹⁾	42,120	31,321	34.5
Sub-total	小計	418,213	364,464	14.7
Overseas	海外			
- ODM customers	- ODM客戶	28,800	31,154	(7.6)
- Distributors	- 經銷商	11,400	7,971	43.0
Sub-total	小計	40,200	39,125	2.7
Total	合計	458,413	403,589	13.6

Note:

(1) Other customers include sales of disposable trocars under non-distributor (logistics partner + academic promotion partner) model in the VBP provinces.

Cost of Sales

Cost of sales during the Reporting Period mainly consisted of raw materials, direct labor cost and manufacturing costs.

For the six months ended June 30, 2024, the Group's cost of sales was RMB95.3 million, representing an increase of 16.4% as compared with RMB81.8 million for the six months ended June 30, 2023. The increase in cost of sales was generally in line with the Group's revenue.

附註：

(1) 其他客戶包括在集採省份的非經銷商（物流夥伴+學術推廣夥伴）模式項下的一次性套管穿刺器銷售。

銷售成本

於報告期內，銷售成本主要包括原材料、直接人工成本及生產成本。

截至2024年6月30日止六個月，本集團的銷售成本為人民幣95.3百萬元，較截至2023年6月30日止六個月的人民幣81.8百萬元增加16.4%。銷售成本增加與本集團收入大致相符。

Management Discussion and Analysis

管理層討論與分析

The following table sets forth the breakdown of cost of sales by nature for the periods indicated:

下表載列於所示期間按性質劃分的銷售成本明細：

		Six months ended June 30, 截至6月30日止六個月			
		2024 2024年		2023 2023年	
		Amount 金額	% of total 佔總額百分比	Amount 金額	% of total 佔總額百分比
RMB'000 (except percentages) (Unaudited) 人民幣千元 (百分比除外) (未經審核)					
Raw materials	原材料	48,796	51.2	42,817	52.3
Direct labor costs	直接人工成本	23,603	24.8	19,486	23.8
Manufacturing costs ⁽¹⁾	生產成本 ⁽¹⁾	22,891	24.0	19,531	23.9
Total	總計	95,290	100.0	81,834	100.0

Note:

附註：

⁽¹⁾ Manufacturing costs primarily include utilities costs, overhead expenses and depreciation of manufacturing equipment.

(1) 生產成本主要包括公用設施成本、管理費用及生產設備的折舊。

Gross Profit and Gross Margin

The Group's gross profit increased by 12.9% to RMB363.1 million for the six months ended June 30, 2024 from RMB321.8 million for the six months ended June 30, 2023, due to an increase in sales.

The Group's gross profit margin was 79.2% for the six months ended June 30, 2024, which remained stable as compared to that of 79.7% for the six months ended June 30, 2023. Specifically, the contribution from newer products such as ultrasonic scalpels and staplers increased during the Reporting Period, whereby these products have a lower gross profit margin than that of the other existing disposable products due to their product type characteristics.

毛利及毛利率

由於銷售額增加，我們的毛利自截至2023年6月30日止六個月的人民幣321.8百萬元增加12.9%至截至2024年6月30日止六個月的人民幣363.1百萬元。

截至2024年6月30日止六個月，本集團的毛利率為79.2%，與截至2023年6月30日止六個月的79.7%相比維持穩定。具體而言，新產品（如超聲切割止血刀及吻合器）於報告期內的貢獻有所增加，但由於此等產品類型特性，其毛利率相對於其他現有一次性產品較低。

Management Discussion and Analysis

管理層討論與分析

The following table sets forth the breakdown of the Group's gross profit and gross profit margin by product type for the periods indicated:

下表載列於所示期間本集團按產品類型劃分的毛利及毛利率明細：

		Six months ended June 30, 截至6月30日止六個月			
		2024 2024年		2023 2023年	
		Gross profit 毛利	Gross profit margin 毛利率	Gross profit 毛利	Gross profit margin 毛利率
RMB'000 (except percentages) (Unaudited) 人民幣千元 (百分比除外) (未經審核)					
Disposable products	一次性產品	335,188	81.9%	286,875	83.9%
Reusable products	重複性產品	27,935	56.7%	34,880	56.7%
Total	總計	363,123	79.2%	321,755	79.7%

Other Income and Gain

Other income and gains for the six months ended June 30, 2024 was RMB115.4 million, while for the six months ended June 30, 2023, it was RMB93.8 million. The increase was primarily due to (i) the increase in interest income of RMB20.0 million as compared to those in the corresponding period in 2023; and (ii) the recognition of a gain arising from the deconsolidation of Weijing Medical of RMB27.3 million which was non-recurring in nature as further explained in the section headed "Investment in Weijing Medical" below.

Selling and Distribution Expenses

Selling and distribution expenses were RMB39.1 million for the six months ended June 30, 2024, representing an increase of 19.9% as compared with RMB32.6 million for the six months ended June 30, 2023. The increase was primarily due to (i) the increase in staff costs for sales personnel along with the expansion of sales and marketing team; and (ii) the increase in marketing-related expenses such as exhibitions and academic promotional activities.

Administrative Expenses

Administrative expenses amounted to RMB50.9 million for the six months ended June 30, 2024, representing an increase of 12.0% as compared with RMB45.4 million for the corresponding period in 2023. The increase was mainly due to the increase in staff personnel costs and environmental landscaping expenses at the Group's headquarters in recognition of the 20th anniversary of its establishment.

其他收入及收益

截至2024年6月30日止六個月，其他收入及收益為人民幣115.4百萬元，而截至2023年6月30日止六個月為人民幣93.8百萬元。有關增加的主要原因為(i)利息收入較2023年同期增加人民幣20.0百萬元；及(ii)確認取消合併唯精醫療產生的收益人民幣27.3百萬元，其屬於非經常性性質，於下文「於唯精醫療的投資」一節進一步說明。

銷售及經銷開支

截至2024年6月30日止六個月，銷售及經銷開支為人民幣39.1百萬元，較截至2023年6月30日止六個月的人民幣32.6百萬元增加19.9%。有關增加乃主要由於(i)隨著銷售及營銷團隊擴大，銷售人員的人員成本增加；及(ii)展覽及學術推廣活動等營銷相關開支增加所致。

行政開支

截至2024年6月30日止六個月，行政開支為人民幣50.9百萬元，較2023年同期的人民幣45.4百萬元增加12.0%。增加的主要原因為增加本集團員工工資及福利，以及環境景觀開支，以紀念本集團成立20週年。

Management Discussion and Analysis

管理層討論與分析

Research and Development Expenses

Research and development expenses for the six months ended June 30, 2024 was RMB43.4 million, representing a decrease of 27.8% as compared with RMB60.1 million for the six months ended June 30, 2023. Such decrease was primarily due to the decrease in research and development expenses contributed by Weijing Medical and consolidated by the Group for lesser months as compared to the corresponding period in 2023 following its deconsolidation from the Group in March 2024, the effect of which was partially offset by the increase in research and development expenses at the Group's headquarters along with the increase in R&D department headcount and its project portfolio.

Other Expenses

Other expenses primarily consist of donation and foreign exchange loss. For the Reporting Period, the Group's other expenses of RMB11.9 million, which was primarily attributable to foreign exchange loss arising from the currency fluctuation of USD against RMB.

Investment in Weijing Medical

Reference is made to the Company's announcements dated January 18, 2022 and March 20, 2024 in relation to the equity investment and deconsolidation of Weijing Medical. On March 20, 2024, the shareholders of Weijing Medical had approved certain amendments to the articles of association and the change in board composition of Weijing Medical. Pursuant to the amended articles of association of Weijing Medical, the number of directors that Kangji Hong Kong is entitled to nominate has decreased from four to three out of seven directors on the board of directors of Weijing Medical ("Weijing Medical Board"). As a result, Kangji Hong Kong ceased to be able to appoint a majority of members on the Weijing Medical Board and lost control over Weijing Medical. Upon the aforementioned change in board composition becoming effective, Weijing Medical had ceased to be a subsidiary of the Company and the financial results of Weijing Medical was no longer consolidated into the consolidated financial statements of the Company. As at the completion date of Weijing Medical's deconsolidation, the Group recorded a gain of RMB27.3 million, which was calculated based on the difference between the fair value of the Group's retained interest in Weijing Medical, as estimated with the assistance of an independent professional valuer, and the Group's share of the carrying value of the assets and liabilities of Weijing Medical. Weijing Medical was accounted for as an investment in an associate in the consolidated financial statements of the Company since then.

研究及開發開支

截至2024年6月30日止六個月，研究及開發開支為人民幣43.4百萬元，較截至2023年6月30日止六個月的人民幣60.1百萬元減少27.8%。有關減少的主要原因為唯精醫療的研發開支減少且與2023年同期相比，唯精醫療自本集團取消合併後的合併月份較少，其影響部分被由本集團總部研發開支增加以及研發部門人數及其項目組合增加所抵銷。

其他開支

其他開支主要包括捐款及匯兌虧損。於報告期內，本集團的其他開支為人民幣11.9百萬元，主要乃由於美元兌人民幣匯率波動產生匯兌損失所致。

於唯精醫療的投資

茲提述本公司日期為2022年1月18日及2024年3月20日的公告，內容有關唯精醫療的股權投資及取消合併。於2024年3月20日，唯精醫療股東已批准唯精醫療組織章程細則若干修訂及董事會組成變動。根據唯精醫療經修訂組織章程細則，康基香港有權委派之董事人數已由唯精醫療董事會（「唯精醫療董事會」）的七名董事其中的四名董事減少至三名。因此，康基香港不可再委任唯精醫療董事會的大部分成員，並失去對唯精醫療之控制。上述董事會組成變動生效後，唯精醫療已不再為本公司之附屬公司，而唯精醫療之財務業績已不再併入本公司綜合財務報表。於唯精醫療取消合併完成日期，本集團錄得收益人民幣27.3百萬元，此乃根據本集團於唯精醫療之保留權益經獨立專業估值師協助下估計之公平值，與本集團佔唯精醫療之資產及負債賬面值之間的差額而計算。自此，唯精醫療於本公司綜合財務報表中入賬列作於一間聯營公司的投資。

Management Discussion and Analysis

管理層討論與分析

In June 2024, the Group acquired an additional 2% equity interest in Weijing Medical (“**Follow-on Acquisition**”) for a cash consideration of RMB10 million from the then existing shareholder of Weijing Medical. Upon the completion of the Follow-on Acquisition and as at June 30, 2024, the Group held as to 37% equity interest in Weijing Medical. Furthermore, the Group paid RMB70 million to Weijing Medical during the Reporting Period to settle part of the contingent consideration payable upon fulfillment of the conditions satisfied by Weijing Medical as stipulated in the relevant investment agreements.

As at June 30, 2024, the Group’s carrying value in Weijing Medical was approximately RMB351.5 million, representing approximately 8.1% of the Group’s total assets. Therefore, the investment in Weijing Medical is considered the Group’s significant investment. No market fair value was available for this private investment as at June 30, 2024.

The principal activities of Weijing Medical is the research and development of, and production of surgical robotic products and instruments for laparoscopic surgery in China. The Group treated its holding of equity interests in Weijing Medical as a long-term investment since January 2022 which is in line with the principal businesses and strategic growth of the Group.

During the Reporting Period, Weijing Medical remained in the product development phase. Consequently, it generated no revenue and incurred a net loss for the period. The Group recognised a share of Weijing Medical’s loss amounting to RMB5.9 million proportionate to its share of equity interest in Weijing Medical, for the period from the completion date of Weijing Medical’s deconsolidation to June 30, 2024. No dividends were distributed by Weijing Medical during the Reporting Period.

Income Tax Expenses

Income tax expenses were RMB52.0 million for the six months ended June 30, 2024, representing an increase of 24.0% as compared to RMB42.0 million for the six months ended June 30, 2023. The increase in income tax expenses was primarily due to the increase in taxable income of the Group’s operating entities and accrued withholding tax chargeable upon repatriation of dividends.

於2024年6月，本集團向唯精醫療當時的原股東收購唯精醫療的額外2%股權（「**後續收購事項**」），現金代價為人民幣10百萬元。於後續收購事項完成後及於2024年6月30日，本集團持有唯精醫療37%股權。此外，本集團於報告期內向唯精醫療支付人民幣70百萬元，用作清償相關投資協議規定的唯精醫療滿足的條件後應付的部分或然代價。

於2024年6月30日，本集團於唯精醫療的賬面值約為人民幣351.5百萬元，佔本集團資產總值約8.1%。因此，於唯精醫療的投資被視為本集團的重大投資。於2024年6月30日，此項私人投資並無市場公允價值可予提供。

唯精醫療的主要業務為在中國從事腹腔鏡手術機器人產品及器械的研發和生產。本集團自2022年1月起將持有唯精醫療股權視為長期投資，符合本集團的主要業務及戰略增長。

報告期內，唯精醫療仍處於產品開發階段。因此，其並無產生收入，並於期內產生淨虧損。於唯精醫療取消合併完成日期至2024年6月30日期間，本集團按其所持唯精醫療股權比例確認應佔唯精醫療虧損人民幣5.9百萬元。於報告期內，唯精醫療並無分派股息。

所得稅開支

截至2024年6月30日止六個月，所得稅開支為人民幣52.0百萬元，較截至2023年6月30日止六個月的人民幣42.0百萬元增加24.0%。所得稅開支增加的主要因為本集團經營實體的應課稅收入及匯回股息應計預扣稅增加。

Management Discussion and Analysis

管理層討論與分析

Non-HKFRS Adjusted Net Profit for the Reporting Period

To supplement the Group's consolidated statement of profit or loss and other comprehensive income which is presented in accordance with HKFRS, we also use adjusted net profit as a non-HKFRS measure, which is not required by, or presented in accordance with, HKFRS. We believe that the presentation of non-HKFRS measure when shown in conjunction with the corresponding HKFRS measures provides useful information to investors and management in facilitating a comparison of the Group's ongoing operating performance from period to period by eliminating potential impacts of certain non-operational or one-off expenses, including fair value gains on financial assets at fair value through profit or loss, foreign exchange difference, share-based payment expenses, investment income from short-term financial products and gain on deconsolidation of Weijing Medical. Such non-HKFRS measure allows investors to consider metrics used by management in evaluating the Group's performance.

The following table shows the Group's adjusted net profit for the Reporting Period and its reconciliation to profit for the periods indicated:

非《香港財務報告準則》經調整報告期內純利

為補充本集團根據《香港財務報告準則》呈列的綜合損益及其他全面收益表，我們亦使用並非《香港財務報告準則》規定或並非按《香港財務報告準則》呈列的經調整純利作為非《香港財務報告準則》計量。我們認為，連同相應《香港財務報告準則》計量一併呈列非《香港財務報告準則》計量，可通過排除若干非經營或一次性開支（包括以公允價值計量且其變動計入當期損益的金融資產的公允價值收益、匯兌差額、以股份為基礎的付款開支、短期金融產品的投資收益取消合併唯精醫療的收益）的潛在影響，為投資者及管理層提供有用資料，協助比較本集團各期間的持續經營表現。該等非《香港財務報告準則》計量允許投資者考慮管理層於評估本集團表現時所採用的標準。

下表載列本集團於報告期內的經調整純利及其與所示期內利潤的對賬：

		Six months ended June 30, 截至6月30日止六個月	
		2024 2024年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Profit for the period attributable to owners of the parent	母公司擁有人應佔期內利潤	285,847	255,461
Add/(Less):	加／(減)：		
Fair value gain on financial assets at fair value through profit or loss ⁽¹⁾	以公允價值計量且其變動計入當期損益的金融資產的公允價值收益 ⁽¹⁾	(46)	(2,269)
Foreign exchange difference ⁽²⁾	匯兌差額 ⁽²⁾	10,984	(23,227)
Share-based payment expenses ⁽³⁾	以股份為基礎的付款開支 ⁽³⁾	6,183	7,273
Investment income on short-term financial products ⁽⁴⁾	短期金融產品的投資收益 ⁽⁴⁾	(842)	(53)
Gain on deconsolidation of Weijing Medical ⁽⁵⁾	取消合併唯精醫療的收益 ⁽⁵⁾	(27,253)	-
Non-HKFRS adjusted net profit for the period attributable to owners of the parent	母公司擁有人應佔非《香港財務報告準則》經調整期內純利	274,873	237,185
Non-HKFRS adjusted earnings per share	非《香港財務報告準則》經調整每股盈利		
- Basic	— 基本	RMB人民幣23.46 cents分	RMB人民幣20.27 cents分
- Diluted	— 攤薄	RMB人民幣23.46 cents分	RMB人民幣20.18 cents分

Management Discussion and Analysis

管理層討論與分析

Notes:

- (1) Fair value gain on equity investment is non-operational in nature which mainly arises from the change in fair value of the Group's investment in Shenzhen Edge Medical Co., Ltd.* (深圳市精鋒醫療科技股份有限公司) for the periods, the amount of which may not directly correlate with the underlying performance of the Group's business operations.
- (2) Foreign exchange difference is non-operational in nature which mainly arises from the currency fluctuation of USD against RMB for the periods, the amount of which may not directly correlate with the underlying performance of the Group's business operations.
- (3) Share-based payment expenses are non-operational expenses arising from granting RSUs and pre-IPO share options to selected management members, the amount of which may not directly correlate with the underlying performance of the Group's business operations, and is also affected by non-operating performance related factors that are not closely or directly related to the Group's business activities.
- (4) Investment income from short-term financial products purchased mainly for hedging foreign currency fluctuations is non-operational in nature which is affected by the currency fluctuation of USD against RMB for the periods, the amount of which may not directly correlate with the underlying performance of the Group's business operations.
- (5) Gain on deconsolidation of Weijing Medical was non-recurring in nature, the amount of which may not directly correlate with the underlying performance of the Group's business operations.

The use of the non-HKFRS measures has limitations as an analytical tool, and it should not be considered in isolation from, or as a substitute for or superior to analysis of, the Group's results of operations or financial condition as reported under HKFRS. In addition, the non-HKFRS financial measure may be defined differently from similar terms used by other companies and therefore may not be comparable to similar measures presented by other companies.

附註：

- (1) 股權投資的公允價值收益屬於非經營性收益，主要來自本集團於有關期間對深圳市精鋒醫療科技股份有限公司投資的公允價值變動，其金額可能與本集團業務營運的基本表現無直接關係。
- (2) 匯兌差額為非經營性質，主要是由於美元兌人民幣於有關期間的匯率波動所致，其金額可能與本集團業務營運的基本表現並無直接關係。
- (3) 以股份為基礎的付款開支乃因授予選定管理層成員受限制股份單位及首次公開發售前購股權而產生的非經營開支，其金額可能與本集團業務營運相關表現無直接關係，且亦受與本集團業務活動並無緊密或直接關係的非經營表現有關因素所影響。
- (4) 所購買主要用於對沖匯兌波幅的短期金融產品的投資收益為非經營性質，主要是由於有關期間內美元兌人民幣的匯率波動所致，其金額可能與本集團業務營運的基本表現無直接關係。
- (5) 取消合併唯精醫療的收益屬於非經常性性質，其金額可能與本集團業務營運的基本表現並非直接相關。

使用非《香港財務報告準則》計量作為分析工具具有局限性，其不應被視為獨立於或可代替或優於本集團根據《香港財務報告準則》報告作出的經營業績或財務狀況的分析。此外，非《香港財務報告準則》財務計量的定義可能與其他公司使用的類似術語不同，因此未必與其他公司呈列的類似計量可資比較。

Management Discussion and Analysis

管理層討論與分析

Liquidity and Capital Resources

During the Reporting Period, the Group financed its operations and other capital expenditure requirements primarily through cash generated from its operations and proceeds from the Company's initial public offering on the Stock Exchange on June 29, 2020.

As of June 30, 2024, the Group had cash and cash equivalents of RMB3,058.9 million (including RMB291.2 million recorded in assets classified as held for sale in the consolidated statement of financial position), as compared with RMB2,973.5 million as of December 31, 2023. During the Reporting Period, the increase in cash and cash equivalents of RMB85.4 million was primarily due to the net cash generated from operations, the effect of which was partly offset by (i) net cash used in investing activities mainly for further investment in Weijing Medical and for purchase of short-term financial products; and (ii) cash used in financing activities mainly for repurchase of the Shares.

As at June 30, 2024, most of the Group's cash and cash equivalents were denominated in RMB, USD and HKD.

Net Current Assets

The Group had net current assets of RMB1,571.4 million as of June 30, 2024, representing a decrease of RMB1,618.5 million as compared with RMB3,189.9 million as of December 31, 2023. The decrease in net current assets was primarily due to the declaration and distribution of final dividend for the year ended December 31, 2023 and special dividend in aggregate amount of RMB1,663.9 million to be payable to the Shareholders in July 2024.

Foreign Exchange Exposure

During the Reporting Period, the Group's operations were primarily based in China. Assets, liabilities and transactions in the PRC are mainly denominated in RMB, while overseas assets and transactions are mainly denominated in USD. We are exposed to foreign currency risks, primarily including account receivables, account payables and cash balances that are denominated in a foreign currency, i.e., a currency other than the functional currency of respective subsidiaries. For the six months ended June 30, 2024, the Group recorded an exchange loss of RMB11.0 million, as compared to an exchange gain of RMB23.2 million for the six months ended June 30, 2023, attributable to the currency fluctuations of USD against RMB.

The Group has been actively monitoring and overseeing its foreign exchange risks and mitigating its potential risk exposure with the use of short-term financial products should the need arise.

流動資金及資本資源

於報告期內，本集團主要通過其經營所得現金及本公司於2020年6月29日在聯交所首次公開發售所得資金為營運及其他資本開支需求提供資金。

截至2024年6月30日，本集團的現金及現金等價物為人民幣3,058.9百萬元（其中人民幣291.2百萬元計入綜合財務狀況表的持作待售資產），而截至2023年12月31日為人民幣2,973.5百萬元。於報告期內，現金及現金等價物增加人民幣85.4百萬元乃主要由於經營所得現金淨額所致，惟部分由以下各項所抵銷(i)主要用於進一步投資唯精醫療的投資活動及購買短期金融產品使用的現金淨額；及(ii)主要用於購回股份使用的現金。

於2024年6月30日，本集團大部分現金及現金等價物以人民幣、美元及港元計值。

流動資產淨值

截至2024年6月30日，本集團的流動資產淨值為人民幣1,571.4百萬元，較截至2023年12月31日的人民幣3,189.9百萬元減少人民幣1,618.5百萬元。流動資產淨值減少的主要因為宣派及派發截至2023年12月31日止年度的末期股息以及將於2024年7月向股東支付合計人民幣1,663.9百萬元之特別股息。

外匯風險

於報告期內，本集團主要於中國營運。中國的資產、負債及交易主要以人民幣計值，海外資產及交易主要以美元計值。我們面臨外匯風險，主要包括以外幣（即相關附屬公司功能貨幣以外的貨幣）計值的應收賬款、應付賬款及現金結餘。截至2024年6月30日止六個月，本集團錄得匯兌虧損人民幣11.0百萬元，而截至2023年6月30日止六個月則為匯兌收益人民幣23.2百萬元，乃由於美元兌人民幣匯率波動所致。

本集團一直積極監控及監督外匯風險，並按需要通過使用短期金融產品降低其潛在風險敞口。

Management Discussion and Analysis

管理層討論與分析

Capital Expenditure

For the six months ended June 30, 2024, the Group's total capital expenditure amounted to approximately RMB33.4 million, which was primarily used in purchase of machinery and equipment and construction of buildings. The Group's capital expenditure for the six months ended June 30, 2023 was approximately RMB34.6 million.

Borrowings

As of June 30, 2024, the Group did not have any outstanding bank loans and other borrowings. We monitor capital using a gearing ratio, which is debt divided by total assets. Debt includes trade payables, other payables and accruals, and lease liabilities. As of June 30, 2024, the gearing ratio of the Group was 6.5% (as of December 31, 2023: 3.8%).

Contingent Liabilities

As of June 30, 2024, the Group did not have any outstanding contingent liabilities.

Charge of Assets/Pledge of Assets

As of June 30, 2024, the Group did not have any charge of assets or pledge of assets.

Material Acquisitions and Disposals and Significant Investments

Please see the section headed "Investment in Weijing Medical" above for further details in respect of the Group's significant investment of Weijing Medical during the Reporting Period.

Save for the abovementioned, the Group did not hold any significant investment, or have any other material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period.

Reference is made to the Company's announcement dated December 28, 2023 in relation to the disposal of Hangzhou Kangji Qipu Medical Instrument Co., Ltd. by Hangzhou Kangji, an indirect wholly-owned subsidiary of the Company. By way of update, as additional time is required to arrange for the completion, the disposal is expected to complete in the second half of 2024. During the six months ended June 30, 2024 and up to the date of this report, the purchaser has paid the Company a non-refundable sum of RMB50 million as part of the consideration pursuant to the terms of the equity transfer agreement for this disposal.

資本開支

截至2024年6月30日止六個月，本集團的總資本開支約為人民幣33.4百萬元，主要用於購買機器及設備及建設樓宇。截至2023年6月30日止六個月，本集團資本開支約為人民幣34.6百萬元。

借款

截至2024年6月30日，本集團並無任何未償還銀行貸款及其他借款。我們使用資本負債比率（債務除以資產總值）監控資金。債務包括貿易應付款項、其他應付款項及預提項目以及租賃負債。截至2024年6月30日，本集團資本負債比率為6.5%（截至2023年12月31日：3.8%）。

或然負債

截至2024年6月30日，本集團並無任何未償還或然負債。

資產抵押／資產質押

截至2024年6月30日，本集團並無抵押或質押任何資產。

重大收購及出售以及重大投資

有關於報告期內本集團於唯精醫療的重大投資的進一步詳情，請參閱上文「於唯精醫療的投資」一節。

除上文披露者外，本集團並無持有任何重大投資，也無任何其他附屬公司、聯營公司及合營企業的重大收購或出售事項。

茲提述本公司日期為2023年12月28日的公告，內容有關Hangzhou Kangji（本公司的間接全資附屬公司）出售Hangzhou Kangji Qipu Medical Instrument Co., Ltd.。根據最新消息，由於需要額外時間安排完成，預計出售事項將於2024年下半年完成。於截至2024年6月30日止六個月及直至本報告日期，買方已根據股權轉讓協議條款就此出售事項向本公司支付不可退還金額人民幣50百萬元，以作為代價的一部分。

Management Discussion and Analysis

管理層討論與分析

Future Plans for Material Investments and Capital Assets

The Group intends to utilize the net proceeds raised from the Company's global offering to pursue strategic investment and to fund acquisition of capital assets for the Group's expansion in the manner set out in the Prospectus and further explained in section headed "Use of Proceeds from the Global Offering" below. Save as disclosed in this report, the Group did not have any plan for material investments and capital assets.

Employee and Remuneration Policy

As of June 30, 2024, the Group had 964 employees (June 30, 2023: 982 employees). Total staff remuneration expenses including remuneration of the Directors and share-based payment expenses for the six months ended June 30, 2024 amounted to RMB73.6 million (for the six months ended June 30, 2023: RMB67.9 million).

The remuneration committee of the Company is responsible for reviewing the Company's emolument policy and structure for all remuneration of the Directors and senior management of the Company. The remuneration of Directors and senior management is determined with reference to the salaries of comparable companies and their experience, duties and performance. The remuneration of other employees is determined with reference to performance, skills, qualifications and experience of the staff concerned and in accordance with the prevailing industry practice.

In recognition of the contributions of the Directors, senior management and employees and to incentivize them to further promote the Group's development, the Company adopted the pre-IPO share option plan and the RSU plan on May 6, 2020. During the Reporting Period, no RSU under the RSU plan were granted to senior management and employees and a total of 16,860,000 RSUs were exercised by the grantees. As of June 30, 2024, a total of 5,525,000 RSUs previously granted remain outstanding under the RSU plan.

未來重大投資及資本資產計劃

本集團擬動用本公司全球發售所籌集的所得款項淨額進行戰略投資，並按招股章程所載及下文「全球發售所得款項用途」一節中進一步解釋的方式為本集團收購資本資產以進行擴張提供資金。除本報告所披露者外，本集團並無有關重大投資及資本資產的任何計劃。

僱員及薪酬政策

截至2024年6月30日，本集團擁有964名僱員（2023年6月30日：982名僱員）。截至2024年6月30日止六個月，員工薪酬開支總額（包括董事薪酬及以股份為基礎的付款開支）為人民幣73.6百萬元（截至2023年6月30日止六個月：人民幣67.9百萬元）。

本公司薪酬委員會負責審核本公司所有董事及高級管理人員薪酬的薪酬政策及架構。董事及高級管理層薪酬參照可比公司薪金以及董事及高級管理層的經驗、職能及表現釐定。其他僱員的薪酬乃參考有關員工的表現、技術、資歷及經驗，並根據現時行業慣例釐定。

為表彰董事、高級管理層及僱員的貢獻，並激勵彼等進一步促進本集團的發展，本公司於2020年5月6日採納首次公開發售前購股權計劃及受限制股份單位計劃。於報告期內，受限制股份單位計劃項下並無受限制股份單位已授予高級管理層及僱員，承授人已行使合共16,860,000個受限制股份單位。截至2024年6月30日，受限制股份單位計劃項下合共5,525,000個先前授出的受限制股份單位尚未行使。

Corporate Governance and Other Information

企業管治及其他資料

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at June 30, 2024, to the best knowledge of the Directors, the interests and short positions of the Directors and chief executive of the Company in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO), which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO); or (b) pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (c) to be notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

Interest in the Company

董事及最高行政人員於股份、相關股份及債權證中擁有的權益及淡倉

於2024年6月30日，據董事所深知，董事及本公司最高行政人員於本公司或其任何相聯法團（定義見《證券及期貨條例》第XV部）的股份、相關股份或債權證中擁有的(a)根據《證券及期貨條例》第XV部第7及8分部須知會本公司及聯交所的權益及淡倉（包括根據《證券及期貨條例》相關規定當作或視作擁有的權益及淡倉）；或(b)根據《證券及期貨條例》第352條規定須登記於該條例所述登記冊的權益及淡倉；或(c)根據標準守則須知會本公司及聯交所的權益及淡倉如下：

於本公司的權益

Name of Director/Chief Executive	Capacity/Nature of interest	Number of Shares	Approximate percentage of shareholding in the total issued share capital (%) 於已發行股本總額的持股概約百分比(%)
董事／最高行政人員姓名	身份／權益性質	股份數目	
Mr. ZHONG Ming 鍾鳴先生	Beneficiary of a trust ^(Note 3) 信託受益人 ^(附註3)	408,500,000 (L)	33.63 (L)
	Interest of spouse ^(Note 5) 配偶權益 ^(附註5)	231,500,000 (L)	19.06 (L)
Ms. SHENTU Yinguang 申屠銀光女士	Beneficiary of a trust ^(Note 4) 信託受益人 ^(附註4)	231,500,000 (L)	19.06 (L)
	Interest of spouse ^(Note 5) 配偶權益 ^(附註5)	408,500,000 (L)	33.63 (L)
Mr. YIN Zixin 尹自鑫先生	Beneficial owner ^(Note 6) 實益擁有人 ^(附註6)	4,125,000 (L)	0.34 (L)

Corporate Governance and Other Information

企業管治及其他資料

Notes:

- (1) The letter “L” denotes the directors’ long position in the Shares.
- (2) The calculation is based on the total number of issued shares of the Company as at June 30, 2024, being 1,214,821,000 Shares.
- (3) Fortune Spring ZM B Limited is owned by Fortune Spring ZM AA Limited and Fortune Spring ZM A Limited as to 99.9% and 0.1%, respectively. Fortune Spring ZM AA Limited is wholly owned by the Fortune Spring ZM Trust, for which Butterfield Trust (Asia) Limited serves as the trustee and Mr. Zhong Ming acts as the settlor and protector.
- (4) Fortune Spring YG B Limited is owned by YG AA Limited and Fortune Spring YG A Limited as to 99.8% and 0.2%, respectively. YG AA Limited is wholly owned by The YG Trust, for which BOS Trustee Limited serves as the trustee, and Ms. Shentu Yinguang acts as the settlor and Mr. Zhong acts as the protector.
- (5) Mr. Zhong Ming and Ms. Shentu Yinguang are spouses, and therefore are deemed to be interested in the Shares held by each other under the SFO.
- (6) Mr. YIN Zixin is interested in 4,125,000 Shares upon exercise of the RSUs granted to him in accordance with the RSU Plan.

Save as disclosed above, as of June 30, 2024, none of the Directors or chief executive of the Company has or is deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which will be required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO); or which will be required to be recorded in the register to be kept by the Company pursuant to Section 352 of the SFO, or which will be required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

附註：

- (1) 字母「L」指董事於股份中的好倉。
- (2) 此乃基於本公司於2024年6月30日已發行股份總數為1,214,821,000股計算。
- (3) Fortune Spring ZM B Limited由Fortune Spring ZM AA Limited及Fortune Spring ZM A Limited分別擁有99.9%及0.1%的權益。Fortune Spring ZM AA Limited由Fortune Spring ZM Trust全資擁有，據此，Butterfield Trust (Asia) Limited為受託人，鍾鳴先生作為委託人及保護人。
- (4) Fortune Spring YG B Limited由YG AA Limited及Fortune Spring YG A Limited分別擁有99.8%及0.2%的權益。YG AA Limited由The YG Trust全資擁有，據此，BOS Trustee Limited為受託人，申屠銀光女士作為委託人及鍾先生作為保護人。
- (5) 鍾鳴先生及申屠銀光女士為夫妻，故根據《證券及期貨條例》彼等被視為於互相持有的股份中擁有權益。
- (6) 尹自鑫先生於根據受限制股份單位計劃於受限制股份單位獲行使時向彼授出的4,125,000股股份中擁有權益。

除上文所披露者外，截至二零二四年六月三十日，概無董事或本公司最高行政人員於本公司或其任何相聯法團（定義見《證券及期貨條例》第XV部）的股份、相關股份或債權證中擁有或被視為擁有任何根據《證券及期貨條例》第XV部第7及8分部須知會本公司及聯交所的權益或淡倉（包括根據《證券及期貨條例》相關規定當作或視作擁有的權益及淡倉）；或須登記於本公司根據《證券及期貨條例》第352條存置的登記冊的權益或淡倉；或根據標準守則須知會本公司及聯交所的權益或淡倉。

Corporate Governance and Other Information

企業管治及其他資料

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at June 30, 2024, to the best knowledge of the Directors, the followings are the persons, other than the Directors or chief executive of the Company, who had interests or short positions in the Shares and underlying Shares which would be required to be notified to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO; or as recorded in the register of interests required to be kept by the Company pursuant to Section 336 of Part XV of the SFO:

主要股東於股份及相關股份中擁有的權益及淡倉

於2024年6月30日，據董事所深知，下列人士（董事或本公司最高行政人員除外）於股份及相關股份中擁有根據《證券及期貨條例》第XV部第2及3分部規定須知會本公司及聯交所的權益或淡倉；或擁有記錄於本公司根據《證券及期貨條例》第XV部第336條須予存置的權益登記冊的權益或淡倉：

Name of Shareholders 股東名稱	Capacity/Nature of interest 身份／權益性質	Total number of Shares 股份總數	Approximate percentage of shareholding (%) 持股概約百分比(%)
Butterfield Trust Limited	Trustee of a trust ^(Note 3) 信託受託人 ^(附註3)	408,500,000 (L)	33.63 (L)
BOS Trustee Limited	Trustee of a trust ^(Note 4) 信託受託人 ^(附註4)	231,500,000 (L)	19.06 (L)
Fortune Spring ZM B Limited	Beneficial owner ^(Note 3) 實益擁有人 ^(附註3)	408,500,000 (L)	33.63 (L)
Fortune Spring YG B Limited	Beneficial owner ^(Note 4) 實益擁有人 ^(附註4)	231,500,000 (L)	19.06 (L)
Keyhole Holding Limited	Beneficial owner ^(Note 5) 實益擁有人 ^(附註5)	216,190,500 (L)	17.80 (L)

Notes:

- (1) The letter "L" denotes long position in the Shares.
- (2) The calculation is based on the total number of issued shares of the Company as at June 30, 2024, being 1,214,821,000 Shares.
- (3) Fortune Spring ZM B Limited is owned by Fortune Spring ZM AA Limited and Fortune Spring ZM A Limited as to 99.9% and 0.1%, respectively. Fortune Spring ZM AA Limited is wholly owned by the Fortune Spring ZM Trust, for which Butterfield Trust (Asia) Limited serves as the trustee and Mr. Zhong Ming acts as the settlor and protector.
- (4) Fortune Spring YG B Limited is owned by YG AA Limited and Fortune Spring YG A Limited as to 99.8% and 0.2%, respectively. YG AA Limited is wholly owned by The YG Trust, for which BOS Trustee Limited serves as the trustee, and Ms. Shentu Yinguang acts as the settlor and Mr. Zhong acts as the protector.

附註：

- (1) 字母「L」指於股份中的好倉。
- (2) 此乃基於本公司於2024年6月30日已發行股份總數為1,214,821,000股計算。
- (3) Fortune Spring ZM B Limited由Fortune Spring ZM AA Limited及Fortune Spring ZM A Limited分別擁有99.9%及0.1%的權益。Fortune Spring ZM AA Limited由Fortune Spring ZM Trust全資擁有，據此，Butterfield Trust (Asia) Limited為受託人，鍾鳴先生作為委託人及保護人。
- (4) Fortune Spring YG B Limited由YG AA Limited及Fortune Spring YG A Limited分別擁有99.8%及0.2%的權益。YG AA Limited由The YG Trust全資擁有，據此，BOS Trustee Limited為受託人，申屠銀光女士作為委託人及鍾先生作為保護人。

Corporate Governance and Other Information

企業管治及其他資料

(5) Each of TPG Keyhole, L.P. (as sole shareholder of Keyhole Holding Limited), TPG Asia GenPar VII, L.P. (as a general partner of TPG Keyhole, L.P.), TPG Asia GenPar VII Advisors, Inc. (as a general partner of TPG Asia GenPar VII, L.P.), TPG Holdings III, L.P. (as the sole shareholder of TPG Asia GenPar VII Advisors, Inc.), TPG Holdings III-A, L.P. (as a general partner of TPG Holdings III, L.P.), TPG Holdings III-A, Inc. (as a general partner of TPG Holdings III-A, L.P.), TPG Group Holdings (SBS), L.P. (as the sole shareholder of TPG Holdings III-A, Inc.), TPG Group Holdings (SBS) Advisors, LLC (as a general partner of TPG Group Holdings (SBS), L.P.) and TPG Group Holdings (SBS) Advisors, Inc. (as the sole member of TPG Group Holdings (SBS) Advisors, LLC) is deemed to be interested in the Shares held by Keyhole Holding Limited under the SFO. TPG Group Holdings (SBS) Advisors, Inc. is controlled by Mr. David Bonderman and Mr. James G. Coulter, who disclaim beneficial ownership of the Shares held by Keyhole Holding Limited except to the extent of their pecuniary interest therein.

Save as disclosed above, as of June 30, 2024, the Directors and the chief executive of the Company are not aware of any other person (other than the Directors or chief executive of the Company) who had an interest or short position in the Shares or underlying Shares which would be required to be notified to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or which will be required to be recorded in the register to be kept by the Company pursuant to Section 352 of the SFO.

(5) TPG Keyhole, L.P. (作為Keyhole Holding Limited的唯一股東)、TPG Asia GenPar VII, L.P. (作為TPG Keyhole, L.P.的普通合夥人)、TPG Asia GenPar VII Advisors, Inc. (作為TPG Asia GenPar VII, L.P.的普通合夥人)、TPG Holdings III, L.P. (作為TPG Asia GenPar VII Advisors, Inc.的唯一股東)、TPG Holdings III-A, L.P. (作為TPG Holdings III, L.P.的普通合夥人)、TPG Holdings III-A, Inc. (作為TPG Holdings III-A, L.P.的普通合夥人)、TPG Group Holdings (SBS), L.P. (作為TPG Holdings III-A, Inc.的唯一股東)、TPG Group Holdings (SBS) Advisors, LLC (作為TPG Group Holdings (SBS), L.P.的普通合夥人)及TPG Group Holdings (SBS) Advisors, Inc. (作為TPG Group Holdings (SBS) Advisors, LLC的唯一股東)根據《證券及期貨條例》均視作於Keyhole Holding Limited持有的股份中擁有權益。TPG Group Holdings (SBS) Advisors, Inc.由David Bonderman先生和James G. Coulter先生控制，彼等放棄Keyhole Holding Limited所持股份的實益擁有權，惟彼等於其中的金錢利益除外。

除上文所披露者外，截至二零二四年六月三十日，董事及本公司最高行政人員並不知悉有任何其他人士（董事或本公司最高行政人員除外）於股份或相關股份中擁有根據《證券及期貨條例》第XV部第2及3分部的規定須知會本公司及聯交所的權益或淡倉，或須登記於本公司根據《證券及期貨條例》第352條存置的登記冊的權益或淡倉。

Corporate Governance and Other Information

企業管治及其他資料

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed in the section headed "Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures" above, at no time during the six months ended June 30, 2024 was the Company or any of its subsidiaries, a party to any arrangement that would enable the Directors to acquire benefits by means of acquisition of the Shares in, or debentures of the Company or any other body corporate, and none of the Directors or any of their spouses or children under the age of 18 were granted any right to subscribe for the equity or debt securities of the Company or any other body corporate or had exercised any such right.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended June 30, 2024, the Company repurchased a total of 5,509,500 Shares on the Stock Exchange at an aggregate consideration of approximately HK\$33.8 million (excluding brokerage fees and taxes) at price ranging from HK\$5.56 to HK\$7.08. 1,450,900 Shares (which have been repurchased by the Company in December 2023 and during the Reporting Period) were cancelled during the six months ended June 30, 2024. The Company repurchased a total of 600,000 Shares during the period from July 1, 2024 to the date of this report and 4,619,000 Shares were cancelled in July 2024. The Directors believe that the share repurchases were in the best interests of the Company and its shareholders and would lead to an enhancement of the net assets value per share and/or earnings per share of the Company.

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed interest in any of the Company's listed Shares (including sale of treasury shares) during the six months ended June 30, 2024. As at June 30, 2024, the Company did not hold any treasury shares.

PRE-IPO SHARE OPTION PLAN AND RSU PLAN

On May 6, 2020, the Company adopted the Pre-IPO Share Option Plan and the RSU Plan, pursuant to which the Company may grant options to subscribe for the Shares and issue certain units of Shares with restrictive rights to eligible participants subject to the terms and conditions stipulated therein. The terms of the Pre-IPO Share Option Plan and the RSU Plan are not subject to the provisions of Chapter 17 of the Listing Rules.

董事收購股份或債權證的權利

除上文「董事及最高行政人員於股份、相關股份及債權證中擁有的權益及淡倉」一節所披露者外，於截至2024年6月30日止六個月期間，本公司或其任何附屬公司概無訂立任何安排，使董事可藉收購本公司或任何其他法人團體的股份或債權證獲得利益，且概無董事或任何彼等的配偶或未滿18歲子女獲授任何權利以認購本公司或任何其他法人團體的權益或債務證券或已行使任何該等權利。

購買、出售或贖回本公司之上市證券

截至2024年6月30日止六個月，本公司於聯交所以總代價約為33.8百萬港元（不包括經紀費用及稅項）回購合共5,509,500股股份，價格介乎5.56港元至7.08港元。截至2024年6月30日止六個月內，已註銷1,450,900股股份（已由本公司於2023年12月及報告期內購回）。本公司於2024年7月1日至本報告日期期間購回合共600,000股股份，並於2024年7月註銷4,619,000股股份。董事相信，股份購回符合本公司及其股東的最佳利益，並將提高本公司每股資產淨值及／或每股盈利。

除上文所披露者外，截至2024年6月30日止六個月，本公司或其任何附屬公司概無購買、出售或贖回本公司任何上市股份（包括庫存股份）的權益。於2024年6月30日，本公司並無持有任何庫存股份。

首次公開發售前購股權計劃及受限制股份單位計劃

於2020年5月6日，本公司採納首次公開發售前購股權計劃及受限制股份單位計劃，據此，本公司可授出認購股份的購股權，並根據其中所載條款及條件向合資格參與者發行帶有限制權利的若干股份單位。首次公開發售前購股權計劃及受限制股份單位計劃的條款不受《上市規則》第十七章條文所規限。

Corporate Governance and Other Information

企業管治及其他資料

The Pre-IPO Share Option Plan and the RSU Plan were adopted to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives to selected employees, Directors and consultants and to promote the success of the Company's business by offering these individuals an opportunity to acquire a proprietary interest in the Company.

(a) Pre-IPO Share Option Plan

As at January 1, 2024 and June 30, 2024, the number of Shares in respect of which options had been granted under the Pre-IPO Share Option Plan was nil.

(b) RSU Plan

The underlying Shares of the RSU Plan are Shares held by Fortune Spring KangJi 1 Limited. The maximum number of RSUs that may be granted under the RSU Plan in aggregate shall be such number of Shares held or to be held by Fortune Spring KangJi 1 Limited from time to time.

As of June 30, 2024, the overall limit on the number of underlying Shares to be granted under the RSU Plan was 29,950,000 Shares, which had been reserved by Fortune Spring KangJi 1 Limited. The RSUs granted under the RSU Plan shall be valid for a period of six years commencing on the date that the RSU Plan is adopted and approved by the Shareholders.

As at January 1, 2024, a total of 26,810,000 RSUs have been granted under the RSU Plan. During the Reporting Period, (i) no additional RSU had been granted or agreed to be granted under the RSU Plan; (ii) 16,860,000 RSUs had been exercised by certain grantees; and (iii) 4,425,000 RSUs had been cancelled pursuant to the RSU Plan. As such, as of June 30, 2024, a total of 5,525,000 RSUs remained outstanding under the RSU Plan.

採納首次公開發售前購股權計劃及受限制股份單位計劃旨在吸引及保留擔任重要職位的最優人才，向選定僱員、董事及顧問提供額外獎勵，以及透過向該等個人提供機會來獲得本公司專有權益以促進本公司取得業務成功。

(a) 首次公開發售前購股權計劃

於2024年1月1日及2024年6月30日，根據首次公開發售前購股權計劃授出的購股權涉及的股份數目為零。

(b) 受限制股份單位計劃

受限制股份單位計劃的相關股份為 Fortune Spring KangJi 1 Limited 持有的股份。受限制股份單位計劃項下合共可授出的受限制股份單位最高數目須為 Fortune Spring KangJi 1 Limited 不時持有或將要持有的股份數目。

截至2024年6月30日，根據受限制股份單位計劃將予授出的相關股份數目的原整體限額為29,950,000股，已由 Fortune Spring KangJi 1 Limited 保留。根據受限制股份單位計劃授出的受限制股份單位有效期為六年，自股東採納及批准受限制股份單位計劃之日起計。

於2024年1月1日，根據受限制股份單位計劃已授予合共26,810,000個受限制股份單位。於報告期內，(i)並無根據受限制股份單位計劃授出或同意將予授出額外受限制股份單位；(ii)16,860,000個受限制股份單位已由若干承授人行使；及(iii)根據受限制股份單位計劃，4,425,000個受限制股份單位已被取消。因此，截至2024年6月30日，受限制股份單位計劃項下合共5,525,000個受限制股份單位仍未行使。

Corporate Governance and Other Information

企業管治及其他資料

The following table sets out the detailed movements of RSUs during the Reporting Period under the RSU Plan:

下表載列於報告期內受限制股份單位計劃項下的受限制股份單位變動詳情：

Grantees	Date of grant	Vesting date/period	Purchase Price	During the Reporting Period 於報告期內					No. of RSUs outstanding as of June 30, 2024 截至2024年6月30日 尚未行使的受限制股份單位數目
				No. of RSUs outstanding as of January 1, 2024 截至2024年1月1日 尚未行使的受限制股份單位數目	No. of RSUs granted	No. of RSUs exercised	No. of RSUs cancelled	No. of RSUs lapsed	
受讓人	授予日期	歸屬日期/期限	購買價						
Director									
董事									
Mr. YIN Zixin 尹自鑫先生	May 6, 2020 2020年5月6日	May 6, 2020 2020年5月6日	RMB6.448 人民幣6.448元	4,125,000	-	(4,125,000)	-	-	-
Five highest paid individuals									
五名最高薪酬人士									
In aggregate 合共	May 6, 2020 2020年5月6日	May 6, 2020 2020年5月6日	RMB6.448 人民幣6.448元	10,720,000	-	(10,720,000)	-	-	-
	March 26, 2021 2021年3月26日	Between March 26, 2022 to March 26, 2026 2022年3月26日至 2026年3月26日	HK\$9.036 9.036港元	3,000,000	-	-	-	-	3,000,000
Other grantees									
其他受讓人									
In aggregate 合共	May 6, 2020 2020年5月6日	May 6, 2020 2020年5月6日	RMB6.448 人民幣6.448元	6,345,000	-	(2,015,000)	(4,330,000)	-	-
	March 26, 2021 2021年3月26日	Between March 26, 2022 to March 26, 2026 2022年3月26日至 2026年3月26日	HK\$9.036 9.036港元	2,620,000	-	-	(95,000)	-	2,525,000
Total 總計				26,810,000	-	(16,860,000)	(4,425,000)	-	5,525,000

Corporate Governance and Other Information

企業管治及其他資料

USE OF PROCEEDS FROM THE GLOBAL OFFERING AND EXTENSION OF THE EXPECTED TIMEFRAME FOR USE OF PROCEEDS

In connection with the Company's IPO, 225,397,500 Shares of US\$0.00001 each were issued at a price of HK\$13.88 per Share for a total cash consideration, after deducting underwriting commissions and related fees and expenses, of approximately HK\$2,952.5 million (equivalent to RMB2,697.1 million) (the "IPO Proceeds"). As at December 31, 2023, the Company has an unutilized net proceeds of approximately RMB1,802.4 million (the "2023 Unutilized Net Proceeds"). On March 20, 2024, the Company announced the change in the use of the 2023 Unutilized Net Proceeds in its annual results announcement for the year ended December 31, 2023 dated March 20, 2024 (the "Announcement").

The net proceeds from the global offering of the Company (adjusted on a pro rata basis based on the actual net proceeds) have been and will be utilized in that same manner, proportion and the expected timeframe as set out in the section headed "Future Plans and Use of Proceeds" in the Prospectus and as amended in the section headed "Use of Proceeds from the Global Offering and Change in Use of Proceeds" in the Announcement, save for the following extension of the expected timeframe for using the unutilized net proceeds.

The Group's new R&D building at its Hangzhou headquarters became operational in June 2024, and there is no immediate need to set up further R&D centers in other cities in China in the foreseeable future. However, the Board considers that it is crucial to maintain some flexibility at this stage by allowing allocation of resources to expand the R&D facilities in this new R&D building. Having considered the above reasons, the Board has determined to extend another two years in the expected timeframe for the full utilization of the unutilized net proceeds in respect of the establishment of R&D centers, and accordingly, the full utilization of such amount allocated has been extended to within four to six years from the date of listing.

全球發售所得款項用途及延長動用所得款項時間表

就本公司的首次公開發售而言，已按每股股份13.88港元的價格發行225,397,500股每股面值0.00001美元的股份，經扣除包銷佣金以及相關費用及開支後，總現金代價約為2,952.5百萬港元（相當於人民幣2,697.1百萬元）（「首次公開發售所得款項」）。於2023年12月31日，本公司有未動用所得款項淨額約人民幣1,802.4百萬元（「2023年未動用所得款項淨額」）。於2024年3月20日，本公司在日期為2024年3月20日的截至2023年12月31日止年度的年度業績公告（「該公告」）中宣佈更改2023年未動用所得款項淨額的用途。

除下列延長動用尚未動用所得款項淨額的預期時間表外，本公司全球發售所得款項淨額（根據實際所得款項淨額按比例予以調整）已經並將按招股章程「未來計劃及所得款項用途」一節所載列及經該公告「全球發售所得款項用途及所得款項用途變動」一節修訂後的相同方式、比例及預期時間表動用。

本集團位於杭州總部的研發大樓已於2024年6月投入運作，在可預見未來並無即時需要在中國其他城市設立更多研發中心。然而，董事會認為現階段保持一定彈性至關重要，以便分配資源擴大這座新研發大樓的研發設施。經考慮上述原因後，董事會決定將悉數動用設立研發中心的尚未動用所得款項淨額的預期時間表進一步延長兩年，因此，悉數動用該筆已獲分配款項的時間已延長至自上市日期起計四至六年內。

Corporate Governance and Other Information

企業管治及其他資料

The table below sets out the planned and revised planned applications of the IPO Proceeds, the revised planned applications of the 2023 Unutilized Net Proceeds and the actual accrued usage up to, and the unutilized net proceeds as at, June 30, 2024:

下表載列首次公開發售所得款項的計劃及經修訂計劃用途、2023年未動用所得款項淨額的經修訂計劃用途以及直至2024年6月30日的實際應計用途及於2024年6月30日的未動用所得款項淨額：

Use of proceeds	Planned applications of the IPO Proceeds	Revised planned application of the IPO Proceeds ⁽¹⁾	Revised planned applications of the 2023 Unutilized Net Proceeds ⁽¹⁾		Utilization during the six months ended June 30, 2024	Actual usage up to June 30, 2024	Unutilized net proceeds as at June 30, 2024	Expected timeframe for unutilized net proceeds (from the Listing Date)
所得款項用途	首次公開發售所得款項計劃用途	經修訂首次公開發售所得款項計劃用途 ⁽¹⁾	2023年未動用所得款項淨額的經修訂計劃用途 ⁽¹⁾		截至2024年6月30日止六個月動用的實際用途	截至2024年6月30日的未動用的實際用途	於2024年6月30日的未動用的未動用所得款項淨額	未動用所得款項淨額預期時間表(自上市日期起)
	(RMB million)	(RMB million)	(RMB million)	(%)	(RMB million)	(RMB million)	(RMB million)	
	(百萬元)	(人民幣百萬元)	(人民幣百萬元)	(%)	(人民幣百萬元)	(人民幣百萬元)	(人民幣百萬元)	
For expanding production capacity and strengthen manufacturing capabilities, including:								
用於擴大產能及加強製造能力，包括：								
to expand production capacity of current products and further automate existing production lines	249.9	264.3	216.3	12.0	25.1	25.1	191.2	within three to five years 於三至五年內
擴大現有產品的產能並進一步使現有生產線自動化								
to build up production capabilities for pipeline products	260.1	275.1	144.2	8.0	19.8	19.8	124.4	within six years 於六年內
增強管線產品的產能								
For funding R&D activities, including:								
用於為研發活動提供資金，包括：								
to establish R&D centers	433.5	458.5	90.1	5.0	12.8	12.8	77.3	within four to six years 於四至六年內
建立研發中心								
for development and expansion of product pipeline	204.0	215.8	180.3	10.0	24.3	24.3	156.0	within five to six years 於五至六年內
開發及擴展產品管線								
For investing in sales and marketing activities, including:								
用於投資銷售及營銷活動，包括：								
to be used in domestic sales and marketing activities ⁽²⁾	382.5	404.5	180.3	10.0	18.5	18.5	161.8	within four to five years 於四至五年內
用於國內的銷售及營銷活動 ⁽²⁾								
to increase overseas sales	127.5	134.9	90.1	5.0	2.9	2.9	87.2	within three to five years 於三至五年內
增加海外銷售								
For funding potential strategic investment and acquisitions	637.5	674.3	360.5	20.0	80.0	80.0	280.5	within five years 於五年內
用於為潛在戰略投資及收購提供資金								
For working capital and general corporate purposes	255.0	269.7	540.6	30.0	44.1	44.1	496.5	within four to six years 於四至六年內
用於營運資金及一般公司用途								
Total	2,550.0	2,697.1	1,802.4	100.0	227.5	227.5	1,574.9	
總計								

Corporate Governance and Other Information

企業管治及其他資料

Notes:

- (1) By excluding the underwriting commissions and related fees and expenses, the actual net proceeds planned for applications amounted to RMB2,697.1 million. Net proceeds were received in HK\$ and translated to RMB for application planning.
- (2) On March 25, 2021, the Board had resolved to change the location of the sales and marketing center to be established from the Group's headquarters to Beijing, which is in line with the Group's latest business strategy and does not deviate from the original planned application of the net proceeds as described in the Prospectus.
- (3) On March 20, 2024, the Board had resolved to change the use of the 2023 Unutilized Net Proceeds, which is in line with the Group's business strategy, and will not result in any material adverse impact on the business and financial performance of the Group. Further details of reasons for such change in use of proceeds were set out in the Announcement.
- (4) The expected timeframe to use the unutilized net proceeds is prepared based on the best estimate made by the Group, which is subject to change according to the current and future development of the market condition.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Guidelines for Securities Transactions by Directors (the "Written Guidelines") on no less exacting terms than the Model Code as its own code of conduct regarding securities transactions by the Directors.

Having made specific enquiry, all of the Directors have confirmed that they have complied with the Model Code and the Written Guidelines during the six months ended June 30, 2024. No incident of non-compliance of the Written Guidelines by the employees who are likely to be in possession of inside information of the Company was noted by the Company.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company is committed to maintaining high standard of corporate governance to safeguard the interests of its shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

附註：

- (1) 經扣除包銷佣金以及相關費用及開支後，計劃應用的實際所得款項淨額為人民幣2,697.1百萬元。所得款項淨額以港元收取並折算為人民幣用於計劃用途。
- (2) 於2021年3月25日，董事會已議決將我們計劃建立的營銷中心的地點從本集團總部變更為北京，這符合本集團的最新業務策略且不會偏離招股章程中所述的所得款項淨額的原定計劃用途。
- (3) 於2024年3月20日，董事會已議決更改2023年未動用所得款項淨額的用途，其符合本集團的業務策略，且將不會對本集團的業務及財務表現造成任何重大不利影響。有關更改所得款項用途理由的進一步詳情載於該公告。
- (4) 使用未動用所得款項淨額的預期時間表乃根據本集團作出的最佳估計編製，並可根據市況的當前及未來發展而作出變動。

遵守《證券交易標準守則》

本公司已採用一套不遜於標準守則的董事證券交易指引（「書面指引」）作為其董事進行證券交易的行為守則。

經作出具體問詢後，全體董事確認彼等於截至2024年6月30日止六個月均遵守標準守則及書面指引。本公司並無發現可能掌握本公司內幕消息的僱員存在不遵守書面指引的情況。

遵守《企業管治守則》

本公司致力於保持高水平的企業管治，以保障其股東權益、提升企業價值、制定其業務策略及政策以及提升其透明度及問責度。

Corporate Governance and Other Information

企業管治及其他資料

The Company has adopted the code provisions of the CG Code as set out in Appendix C1 to the Listing Rules as its own code of corporate governance.

The Board is of the view that the Company has complied with all applicable code provisions of the CG Code during the Reporting Period, except for a deviation from the code provision C.2.1 of the CG Code, the roles of chairman and chief executive officer of the Company are not separate and are both performed by Mr. ZHONG Ming. The Company has a professional management team to monitor the operations of the subsidiaries. The Board considers that vesting the roles of chairman and chief executive officer in the same person is more efficient in the direction and management of the Company and does not impair the balance of power and authority of the Board and the management of the business of the Group. The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

REVIEW OF INTERIM RESULTS

The Audit Committee consists of two independent non-executive Directors, Mr. CHEN Weibo and Mr. JIANG Feng, and one non-executive Director, Ms. CAI Li. The chairman of the Audit Committee is Mr. CHEN Weibo. The Audit Committee has reviewed the interim report of the Group for the six months ended June 30, 2024 and has recommended for the Board's approval thereof.

The Audit Committee has reviewed together with the management the accounting principles and policies adopted by the Group and the interim condensed consolidated financial information for the six months ended June 30, 2024. The Audit Committee was satisfied that such consolidated financial information were prepared in accordance with the applicable accounting standards and fairly present the Group's financial position and results for the Reporting Period.

EVENTS AFTER THE REPORTING PERIOD

No significant event has occurred since the end of the Reporting Period and up to the date of this report.

INTERIM DIVIDEND

The Board did not recommend the payment of any interim dividend for the six months ended June 30, 2024.

CHANGES IN INFORMATION IN RESPECT OF DIRECTORS

There has been no change in the information of the Directors during the Reporting Period that is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

本公司已採用《上市規則》附錄C1所載《企業管治守則》的守則條文作為其本身之企業管治守則。

董事會認為，本公司於報告期內一直遵守《企業管治守則》內的所有適用守則條文，惟就偏離《企業管治守則》中的守則條文第C.2.1條而言，本公司主席與行政總裁的職位並非分開，均由鍾鳴先生擔任。本公司擁有專業管理團隊監管其附屬公司的經營。董事會認為，主席及行政總裁的職位由同一人兼任能更有效率地引領及管理本公司，且並不損害董事會與本集團業務管理層之間的權責平衡。董事會將不時審閱企業管治架構及慣例，並會在其認為適當時作出必要安排。

審查中期業績

審核委員會由兩名獨立非執行董事陳衛波先生及姜峰先生以及一名非執行董事蔡俐女士組成。審核委員會的主席為陳衛波先生。審核委員會已審查本集團截至2024年6月30日止六個月的中期報告，並建議董事會批准。

審核委員會已連同管理層審查本集團採用的會計原則及政策，以及截至2024年6月30日止六個月的中期簡明綜合財務資料。審核委員會信納，該等綜合財務資料乃根據適用的會計準則編製，並公平呈列了本集團於報告期內的財務狀況及業績。

報告期後事項

報告期末後及截至本報告日期並無重大事項發生。

中期股息

董事會不建議支付截至2024年6月30日止六個月的任何中期股息。

有關董事資料的變更

於報告期內，概無根據《上市規則》第13.51B(1)條須予披露的董事資料變更。

Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		Notes	2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
		附註		
REVENUE	收入	4	458,413	403,589
Cost of sales	銷售成本		(95,290)	(81,834)
Gross profit	毛利		363,123	321,755
Other income and gains	其他收入及收益	4	115,403	93,775
Selling and distribution expenses	銷售及經銷開支		(39,062)	(32,553)
Administrative expenses	行政開支		(50,854)	(45,416)
Research and development costs	研發成本		(43,354)	(60,076)
Reversal of impairment losses/(impairment losses) on financial assets, net	金融資產的減值虧損撥回/(減值虧損)淨額		842	(1,647)
Other expenses	其他開支		(11,883)	(3,379)
Share of losses of an associate	分佔一間聯營公司虧損		(5,868)	-
Finance costs	融資成本		(614)	(1,177)
PROFIT BEFORE TAX	稅前利潤	5	327,733	271,282
Income tax expense	所得稅開支	6	(52,047)	(41,985)
PROFIT FOR THE PERIOD	期內利潤		275,686	229,297
Attributable to:	以下人士應佔：			
Owners of the parent	母公司擁有人		285,847	255,461
Non-controlling interests	非控股權益		(10,161)	(26,164)
			275,686	229,297
OTHER COMPREHENSIVE INCOME	其他全面收益			
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:	於後續期間可能重新分類至損益的其他全面收益/(虧損)：			
Exchange differences on translation of foreign operations	海外業務換算匯兌差額		1,854	(3,057)
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	後續期間可能重新分類至損益的其他全面收益/(虧損)淨額		1,854	(3,057)

Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
	Note 附註		
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	期內除稅後其他全面收益／(虧損)	1,854	(3,057)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	期內全面收益總額	277,540	226,240
Attributable to:	以下人士應佔：		
Owners of the parent	母公司擁有人	287,701	252,404
Non-controlling interests	非控股權益	(10,161)	(26,164)
		277,540	226,240
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	母公司普通股持有人應佔每股盈利		
Basic	基本	RMB24.39cents 人民幣24.39分	RMB21.83cents 人民幣21.83分
Diluted	攤薄	RMB24.39cents 人民幣24.39分	RMB21.73cents 人民幣21.73分

Interim Condensed Consolidated Statement of Financial Position

中期簡明綜合財務狀況表

30 June 2024

2024年6月30日

			30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
	Notes 附註			
NON-CURRENT ASSETS	非流動資產			
Property, plant and equipment	物業、廠房及設備	9	229,495	220,874
Prepayments for property, plant and equipment	物業、廠房及設備預付款項		2,005	412
Right-of-use assets	使用權資產		31,918	64,904
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產		141,718	141,718
Goodwill	商譽		-	167,209
Intangible assets	無形資產		-	284,694
Investment in an associate	於一間聯營公司的投資	10	351,476	-
Deferred tax assets	遞延稅項資產		3,856	3,318
Time deposits	定期存款	13	50,000	-
Total non-current assets	非流動資產總值		810,468	883,129
CURRENT ASSETS	流動資產			
Inventories	存貨		103,848	105,205
Trade receivables	貿易應收款項	11	217,446	225,534
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	12	117,521	9,711
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產		61,116	11,449
Cash and cash equivalents	現金及現金等價物	13	2,717,713	2,676,588
Assets of a disposal group classified as held for sale	分類為持作出售的出售組別資產		3,217,644	3,028,487
Total current assets	流動資產總值		3,553,828	3,380,689
CURRENT LIABILITIES	流動負債			
Trade payables	貿易應付款項	14	30,149	34,146
Other payables and accruals	其他應付款項及預提項目	15	245,223	82,084
Lease liabilities	租賃負債		3,957	6,107
Dividend payable	應付股息		1,663,886	-
Deferred income	遞延收入		318	636
Tax payable	應付稅項		35,958	63,211
Liabilities directly associated with the assets classified as held for sale	與分類為持作出售的資產直接相關的負債		1,979,491	186,184
Total current liabilities	流動負債總額		2,987	4,640
NET CURRENT ASSETS	流動資產淨值		1,982,478	190,824
TOTAL ASSETS LESS CURRENT LIABILITIES	資產總值減流動負債		1,571,350	3,189,865
			2,381,818	4,072,994

Interim Condensed Consolidated Statement of Financial Position

中期簡明綜合財務狀況表

30 June 2024

2024年6月30日

		Note 附註	30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
TOTAL ASSETS LESS CURRENT LIABILITIES	資產總值減流動負債		2,381,818	4,072,994
NON-CURRENT LIABILITIES	非流動負債			
Lease liabilities	租賃負債		3,263	37,883
Deferred tax liabilities	遞延稅項負債		15,827	91,265
Total non-current liabilities	非流動負債總額		19,090	129,148
Net assets	資產淨值		2,362,728	3,943,846
EQUITY	權益			
Equity attributable to owners of the parent	母公司擁有人應佔權益			
Share capital	股本	16	85	86
Reserves	儲備		2,362,643	3,649,676
			2,362,728	3,649,762
Non-controlling interests	非控股權益		-	294,084
Total equity	權益總額		2,362,728	3,943,846

Interim Condensed Consolidated Statement of Changes in Equity

中期簡明綜合權益變動表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔											
		Share capital	Share premium account*	Share held for share award arrangement*	Treasury shares*	Capital reserve*	Share option and award reserve*	Statutory surplus reserve*	Exchange fluctuation reserve*	Retained profits*	Total	Non-controlling interests	Total equity
		股本	股份溢價賬*	持有的股份*	庫存股份*	資本儲備*	購股權及獎勵儲備*	法定盈餘儲備*	匯率波動儲備*	保留利潤*	總計	非控股權益	權益總額
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
At 31 December 2023 (audited)	於2023年12月31日(經審核)	86	2,462,278	(3)	(2,873)	33,301	36,700	181,991	(162,074)	1,100,356	3,649,762	294,084	3,943,846
Profit for the period	期內利潤	-	-	-	-	-	-	-	-	285,847	285,847	(10,161)	275,686
Other comprehensive income for the period:	期內其他全面虧損:												
Exchange differences related to foreign operations	海外業務換算匯兌差額	-	-	-	-	-	-	-	1,854	-	1,854	-	1,854
Total comprehensive income for the period	期內全面收益總額	-	-	-	-	-	-	-	1,854	285,847	287,701	(10,161)	277,540
Shares repurchased	已購回股份	-	-	-	(30,805)	-	-	-	-	-	(30,805)	-	(30,805)
Shares cancelled	已註銷股份	(1)	(12,083)	-	12,084	-	-	-	-	-	-	-	-
Dividend declared	已宣派股息	-	(651,680)	-	-	-	-	-	-	(1,007,140)	(1,658,820)	-	(1,658,820)
Share-based payments	以股份為基礎的付款	-	-	-	-	-	6,183	-	-	-	6,183	-	6,183
Exercise of restricted share units	行使受限制股份單位	-	133,917	1	-	-	(25,211)	-	-	-	108,707	-	108,707
Deconsolidation of a subsidiary (note 17)	取消合併一間附屬公司(附註17)	-	-	-	-	-	-	-	-	-	-	(283,923)	(283,923)
Transfer of share award reserve upon the cancellation of restricted share units	於註銷受限制股份單位時轉撥股份獎勵儲備	-	-	-	-	-	(5,061)	-	-	5,061	-	-	-
Transfer to statutory surplus reserve	轉撥至法定盈餘儲備	-	-	-	-	-	-	24,915	-	(24,915)	-	-	-
At 30 June 2024 (unaudited)	於2024年6月30日(未經審核)	85	1,932,432	(2)	(21,594)	33,301	12,611	206,906	(160,220)	359,209	2,362,728	-	2,362,728

* These reserve accounts comprise the consolidated reserves of RMB2,362,643,000 in the interim condensed consolidated statement of financial position as at 30 June 2024.

* 在2024年6月30日的中期簡明綜合財務狀況表中，該等儲備賬包括合併儲備人民幣2,362,643,000元。

Interim Condensed Consolidated Statement of Changes in Equity

中期簡明綜合權益變動表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

For the six months ended 30 June 2023

截至2023年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔											
		Share capital	Share premium account	Share held for share award arrangement	Treasury shares	Capital reserve	Share option and award reserve	Statutory surplus reserve	Exchange fluctuation reserve	Retained profits	Total	Non-controlling interests	Total equity
		股本	股份溢價賬	獎勵安排持有的股份	庫存股份	資本儲備	關股權及獎勵儲備	法定盈餘儲備	匯率波動儲備	保留利潤	總計	非控股權益	權益總額
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
At 31 December 2022 (audited)	於2022年12月31日(經審核)	86	2,481,480	(3)	(5,495)	33,301	37,252	128,314	(159,123)	857,186	3,372,998	345,810	3,718,808
Profit for the period	期內利潤	-	-	-	-	-	-	-	-	255,461	255,461	(26,164)	229,297
Other comprehensive income for the period:	期內其他全面收益：												
Exchange differences related to foreign operations	海外業務換算匯兌差額	-	-	-	-	-	-	-	(3,057)	-	(3,057)	-	(3,057)
Total comprehensive income for the period	期內全面收益總額	-	-	-	-	-	-	-	(3,057)	255,461	252,404	(26,164)	226,240
Shares repurchased	已購回股份	-	-	-	(13,707)	-	-	-	-	-	(13,707)	-	(13,707)
Shares cancelled	已註銷股份	-	(19,202)	-	19,202	-	-	-	-	-	-	-	-
Dividend declared	已宣派股息	-	-	-	-	-	-	-	-	(216,349)	(216,349)	-	(216,349)
Share-based payments	以股份為基礎的付款	-	-	-	-	-	7,273	-	-	-	7,273	-	7,273
Transfer to statutory surplus reserve	轉撥至法定盈餘儲備	-	-	-	-	-	-	23,776	-	(23,776)	-	-	-
At 30 June 2023 (unaudited)	於2023年6月30日(未經審核)	86	2,462,278	(3)	-	33,301	44,525	152,090	(162,180)	872,522	3,402,619	319,646	3,722,265

Interim Condensed Consolidated Statement of Cash Flows

中期簡明綜合現金流量表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

	Notes 附註	2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
CASH FLOWS FROM OPERATING ACTIVITIES	經營活動所得現金流量		
Profit before tax	稅前利潤	327,733	271,282
Adjustments for:	就下列項目作出調整：		
Finance costs	融資成本	614	1,177
Share of losses of an associate	分佔一間聯營公司虧損	5,868	-
Bank interest income	銀行利息收益	(62,630)	(42,636)
Foreign exchange differences, net	匯兌差額淨額	10,984	(23,227)
Investment income from financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產的投資收益	(842)	(53)
Fair value gains on financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產的公允價值收益	(46)	(2,269)
Loss/(gain) on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的虧損／(收益)	83	(57)
Depreciation of property, plant and equipment	物業、廠房及設備折舊	9,943	10,659
Depreciation of right-of-use assets	使用權資產折舊	4,174	5,378
Amortisation of intangible assets	無形資產攤銷	62	125
(Reversal of impairment losses)/ impairment losses of trade receivables, net	貿易應收款項(減值虧損撥回)／減值虧損淨額	(842)	1,647
Recognition of deferred income	確認遞延收入	(318)	(318)
Lease modification	租賃修訂	6	(304)
Gain on deconsolidation of a subsidiary	取消合併一間附屬公司的收益	(27,253)	-
Share-based payment expense	以股份為基礎的付款開支	6,183	7,273
		273,719	228,677
Increase in inventories	存貨增加	(15,176)	(7,349)
Decrease/(increase) in trade receivables	貿易應收款項減少／(增加)	19,701	(7,651)
(Increase)/decrease in prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產(增加)／減少	(2,028)	3,502
Increase in trade payables	貿易應付款項增加	1,003	8,590
Decrease in other payables and accruals	其他應付款項及預提項目減少	(3,846)	(20,897)
Increase in deferred income	遞延收入增加	-	1,185
Cash generated from operations	經營產生的現金	273,373	206,057
Interest received	已收利息	36,447	9,268
Income tax paid	已付所得稅	(88,098)	(45,775)
Net cash flows from operating activities	經營活動所得現金流量淨額	221,722	169,550

Interim Condensed Consolidated Statement of Cash Flows

中期簡明綜合現金流量表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Net cash flows from operating activities	經營活動所得現金流量淨額	221,722	169,550
CASH FLOWS FROM/(USED IN) INVESTING ACTIVITIES	投資活動所得／(所用) 現金流量		
Purchases of items of property, plant and equipment	購買物業、廠房及設備項目	(35,300)	(23,619)
Purchases of items of intangible assets	購買無形資產項目	-	(39)
Purchases of right-of-use assets	購買使用權資產	-	(854)
Proceeds from disposal of items of property, plant and equipment	出售物業、廠房及設備項目所得款項	211	481
Purchases of financial assets at fair value through profit or loss	購買以公允價值計量且其變動計入當期損益的金融資產	(623,000)	(9,179)
Proceeds from sales of financial assets at fair value through profit or loss	出售以公允價值計量且其變動計入當期損益的金融資產的所得款項	573,100	9,179
Investment income from financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產的投資收益	1,121	48
Interest received	已收利息	82,960	-
Decrease/(increase) in time deposits with original maturity of over three months	原定期限超過三個月的定期存款減少／(增加)	1,253,101	(1,225,916)
Disposal of a subsidiary	出售一間附屬公司	50,000	-
Additional investment in an associate	於一間聯營公司的投資增加	(80,000)	-
Deconsolidation of a subsidiary	取消合併一間附屬公司	(8,829)	-
Net cash flows from/(used in) investing activities	投資活動所得／(所用) 現金流量淨額	1,213,364	(1,249,899)
CASH FLOWS USED IN FINANCING ACTIVITIES	融資活動所用現金流量		
Shares repurchased	已購回股份	(30,805)	(13,707)
Principal portion of lease payments	租賃付款本金部分	(4,887)	(5,895)
Net cash flows used in financing activities	融資活動所用現金流量淨額	(35,692)	(19,602)

Interim Condensed Consolidated Statement of Cash Flows

中期簡明綜合現金流量表

For the six months ended 30 June 2024

截至2024年6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	現金及現金等價物 增加／(減少) 淨額	1,399,394	(1,099,951)
Cash and cash equivalents at beginning of period	期初現金及現金等價物	1,520,397	1,738,963
Effect of foreign exchange rate changes, net	匯率變動的影響淨額	(4,063)	24,732
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末現金及現金等價物	2,915,728	663,744
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS	現金及現金等價物結餘分析		
Cash and cash equivalents as stated in the condensed consolidated statement of financial position	簡明綜合財務狀況表內所述的 現金及現金等價物	2,767,713	3,002,425
Cash and cash equivalents attributable to a disposal group classified as held for sale	分類為持作出售的出售組別應佔 現金及現金等價物	291,193	-
Time deposits with original maturity of over three months when acquired	於購入時原定期限超過三個月的 定期存款	(143,178)	(2,338,681)
Cash and cash equivalents as stated in the condensed consolidated statement of cash flows	簡明綜合現金流量表內的 現金及現金等價物	2,915,728	663,744

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2024 has been prepared in accordance with Hong Kong Accounting Standard (“HKAS”) 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2023.

2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2023, except for the adoption of the following new and revised Hong Kong Financial Reporting Standards (“HKFRSs”) for the first time for the current period’s financial information.

Amendments to HKFRS 16	<i>Lease Liability in a Sale and Leaseback</i>
Amendments to HKAS 1	<i>Classification of Liabilities as Current or Non-current</i> (the “2020 Amendments”)
Amendments to HKAS 1	<i>Non-current Liabilities with Covenants</i> (the “2022 Amendments”)
Amendments to HKAS 7 and HKFRS 7	<i>Supplier Finance Arrangements</i>

The nature and impact of the revised HKFRSs are described below:

- (a) Amendments to HKFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains. Since the Group has no sale and leaseback transactions with variable lease payments that do not depend on an index or a rate occurring from the date of initial application of HKFRS 16, the amendments did not have any impact on the financial position or performance of the Group.

1. 編製基準

截至2024年6月30日止六個月的中期簡明綜合財務資料乃按照《香港會計準則》（「香港會計準則」）第34號中期財務報告編製。中期簡明綜合財務資料並不包括年度財務報表所要求的全部資料及披露，故應與本集團截至2023年12月31日止年度的年度綜合財務報表一併閱讀。

2. 會計政策及披露的變動

除就本期間財務資料首次採納的以下新訂及經修訂香港財務報告準則（「《香港財務報告準則》」）外，編製中期簡明綜合財務資料所採納的會計政策與編製本集團截至2023年12月31日止年度的年度綜合財務報表所應用者一致。

《香港財務報告準則》 第16號修訂本	售後租回的租賃 負債
《香港會計準則》 第1號修訂本	負債分類為流動或 非流動（「2020年 修訂」）
《香港會計準則》 第1號修訂本	附帶契諾的非流動負 債（「2022年 修訂」）
《香港會計準則》 第7號及《香港財務 報告準則》 第7號修訂本	供應商融資安排

經修訂香港財務報告準則的性質及影響描述如下：

- (a) 《香港財務報告準則》第16號修訂本訂明賣方一承租人於計量售後回租交易產生的租賃負債所用的規定，以確保賣方一承租人不會確認與所保留使用權有關的任何損益金額。由於自首次適用香港財務報告準則第16號之日起，本集團並無發生可變租賃付款不依賴指數或利率的售後租回交易，因此該等修訂對本集團的財務狀況或表現並無任何影響。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

- (b) The 2020 Amendments clarify the requirements for classifying liabilities as current or non-current, including what is meant by a right to defer settlement and that a right to defer must exist at the end of the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement. The amendments also clarify that a liability can be settled in its own equity instruments, and that only if a conversion option in a convertible liability is itself accounted for as an equity instrument would the terms of a liability not impact its classification. The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

The Group has reassessed the terms and conditions of its liabilities as at 1 January 2023 and 2024 and concluded that the classification of its liabilities as current or non-current remained unchanged upon initial application of the amendments. Accordingly, the amendments did not have any impact on the financial position or performance of the Group.

- (c) Amendments to HKAS 7 and HKFRS 7 clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk. The disclosure of relevant information for supplier finance arrangements is not required for any interim reporting period during the first annual reporting period in which an entity applies the amendments. As the Group does not have supplier finance arrangements, the amendments did not have any impact on the interim condensed consolidated financial information.

2. 會計政策及披露的變動 (續)

- (b) 2020年修訂澄清有關將負債分類為即期或非即期的規定，包括延遲清償權的含義，以及延遲清償權必須在報告期末存在。負債的分類不受實體行使其延遲清償權的可能性的影響。該等修訂亦澄清，負債可以用其自身的權益工具清償，以及只有當可轉換負債中的轉換選擇權本身作為權益工具入賬時，負債的條款才不會影響其分類。2022年修訂進一步澄清，在貸款安排產生的負債契約中，只有實體於報告日或之前必須遵守的契約才會影響負債分類為即期或非即期。對於實體於報告期後12個月內必須遵守未來契約的非流動負債，須進行額外披露。

本集團已重新評估其於2023年及2024年1月1日的負債條款及條件，結論為在首次應用該等修訂後，其負債的流動或非流動分類保持不變。因此，該等修訂並無對本集團的財務狀況或表現產生任何影響。

- (c) 《香港會計準則》第7號及《香港財務報告準則》第7號修訂本闡明供應商融資安排的特點，並規定須就該等安排作出額外披露。該等修訂的披露規定旨在協助財務報表使用者了解供應商融資安排對實體的負債、現金流量及流動資金風險的影響。實體應用該等修訂的第一個年度報告期的任何中期報告期，毋須披露供應商融資安排的相關資料。由於本集團並無供應商融資安排，故該等修訂對中期簡明綜合財務資料並無任何影響。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their products and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

3. 經營分部資料

為便於管理，本集團並無根據其產品劃分為業務單位，而是僅有一個須予報告經營分部。管理層會監察本集團經營分部的整體經營業績，以便就資源分配作出決策以及進行表現評估。

4. 收入、其他收入及收益

收入的分析如下：

	For the six months ended 30 June 截至6月30日止六個月	
	2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Revenue from contracts with customers 來自客戶合約的收入	458,413	403,589

Revenue from contracts with customers

(a) Disaggregated revenue information

來自客戶合約的收入

(a) 細分收入資料

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Type of goods	貨品類型		
Sale of medical instruments	銷售醫療器械	458,413	403,589
Geographical markets	地區市場		
Chinese Mainland	中國內地	418,213	364,464
Other countries/regions	其他國家／地區	40,200	39,125
Total	總計	458,413	403,589
Timing of revenue recognition	收入確認時間		
Goods transferred at a point in time	於某一時間點轉讓的貨品	458,413	403,589

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

4. REVENUE, OTHER INCOME AND GAINS (continued)

Revenue from contracts with customers (continued)

(b) Performance obligation

Information about the Group's performance obligation is summarised below:

Sale of medical instruments

The performance obligation is satisfied upon acceptance of the goods and payment is generally due within one month, extending up to two to six months for certain customers.

An analysis of other income and gains is as follows:

4. 收入、其他收入及收益 (續)

來自客戶合約的收入 (續)

(b) 履約責任

有關本集團履約責任的資料概述如下：

銷售醫療器械

履約責任在接受貨物時履行，付款通常於一個月內到期，若干客戶最多可延長兩至六個月。

其他收入及收益的分析如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Bank interest income	銀行利息收入	62,630	42,636
Gain on deconsolidation of a subsidiary (note 17)	取消合併一間附屬公司的收益 (附註17)	27,253	-
Government grants	政府補助	24,120	25,200
Foreign exchange gains, net	匯兌收益淨額	-	23,227
Fair value gains on financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產的公允價值收益	46	2,269
Investment income from financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產的投資收益	842	53
Others	其他	512	390
Total	總計	115,403	93,775

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/ (crediting):

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Cost of inventories sold	已售存貨成本	90,510	80,372
(Reversal of impairment losses)/ impairment losses of trade receivables, net	貿易應收款項(減值虧損 撥回) / 減值虧損 淨額	(842)	1,647
Government grants	政府補助	(24,120)	(25,200)
Loss/(gain) on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的 虧損 / (收益)	83	(57)
Foreign exchange differences, net	匯兌差額淨額	10,984	(23,227)
Gain on deconsolidation of a subsidiary (note 17)	取消合併一間附屬公司的 收益(附註17)	(27,253)	-
Share-based payment expense	以股份為基礎的付款開支	6,183	7,273

6. INCOME TAX

The Group is subject to income tax on an entity basis on profit arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the Cayman Islands, the Company is not subject to any income tax in this jurisdiction.

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the relevant tax law of the Hong Kong Special Administrative Region, Hong Kong profits tax has been provided at the rate of 16.5% (2023: 16.5%) on the estimated assessable profits arising in Hong Kong during the period. The first HK\$2,000,000 (2023: HK\$2,000,000) of assessable profits of this subsidiary are taxed at 8.25% (2023: 8.25%) and the remaining assessable profits are taxed at 16.5% (2023: 16.5%).

5. 稅前利潤

本集團的稅前利潤乃經扣除 / (計入) 以下各項後得出：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Cost of inventories sold	已售存貨成本	90,510	80,372
(Reversal of impairment losses)/ impairment losses of trade receivables, net	貿易應收款項(減值虧損 撥回) / 減值虧損 淨額	(842)	1,647
Government grants	政府補助	(24,120)	(25,200)
Loss/(gain) on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的 虧損 / (收益)	83	(57)
Foreign exchange differences, net	匯兌差額淨額	10,984	(23,227)
Gain on deconsolidation of a subsidiary (note 17)	取消合併一間附屬公司的 收益(附註17)	(27,253)	-
Share-based payment expense	以股份為基礎的付款開支	6,183	7,273

6. 所得稅

本集團須按實體基準就來自或源自本集團成員公司所處或經營所在司法管轄區的利潤繳納所得稅。

根據開曼群島的規則及法規，本公司在該司法管轄區無需繳納任何所得稅。

本集團須按實體基準就來自或源自本集團成員公司所處或經營所在司法管轄區的利潤繳納所得稅。

根據香港特別行政區的相關稅法，香港利得稅乃就期內於香港產生的估計應課稅利潤按稅率16.5% (2023年：16.5%) 作出撥備。該附屬公司的首2,000,000港元 (2023年：2,000,000港元) 應課稅利潤按8.25% (2023年：8.25%) 稅率繳稅，餘下應課稅利潤按16.5% (2023年：16.5%) 稅率繳稅。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

6. INCOME TAX (continued)

Pursuant to the rules and regulations of Singapore, Singapore profits tax has been provided at the rate of 17% (2023: 17%) on the estimated assessable profits arising in Singapore during the period.

The provision for Chinese Mainland current income tax is based on the statutory rate of 25% of the assessable profits of certain PRC subsidiaries of the Group as determined in accordance with the PRC Corporate Income Tax Law which was approved and became effective on 1 January 2008, except for certain subsidiaries of the Group in Chinese Mainland which are granted tax concessions and are taxed at preferential tax rates.

Pursuant to the Corporate Income Tax Law of the PRC and the respective regulations, preferential tax treatment is available to Hangzhou Kangji Medical Instrument Ltd., since it was recognised as a High and New Technology Enterprise and was entitled to a preferential tax rate of 15% (2023: 15%) during the period. Certain subsidiaries operating in Chinese Mainland were identified as a Small and Micro Enterprise and were entitled to a preferential tax rate of 5.0% (2023: 5.0%) during the period.

The Group calculates the income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the interim condensed consolidated statement of profit or loss and other comprehensive income are:

6. 所得稅 (續)

根據新加坡的規則及法規，新加坡利得稅乃就期內於新加坡產生的估計應課稅利潤按稅率17%（2023年：17%）作出撥備。

中國內地即期所得稅撥備乃根據於2008年1月1日批准生效的《中華人民共和國企業所得稅法》就本集團若干中國附屬公司的應課稅利潤按25%的法定稅率計提，惟本集團於中國內地的若干附屬公司獲授稅務優惠並按優惠稅率繳稅除外。

根據《中華人民共和國企業所得稅法》及相關法規，杭州康基醫療器械有限公司可享受稅收優惠待遇，因為其被認定為高新技術企業，並在期內享有15%（2023年：15%）的優惠稅率。若干於中國內地營運的附屬公司被確定為小微企業，並在期內享有5.0%（2023年：5.0%）的優惠稅率。

本集團使用預期年度總收益適用的稅率計算所得稅開支。中期簡明綜合損益及其他全面收益表中所得稅開支的主要組成部分為：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Current – Chinese Mainland:	即期－中國內地：		
Charge for the period	期內扣除	61,832	36,301
Current tax – Hong Kong	即期稅項－香港	146	–
Deferred	遞延	(9,931)	5,684
Total	總計	52,047	41,985

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

7. DIVIDENDS

On 27 May 2024, the final dividend of RMB41 cents per ordinary share and a special dividend of RMB99 cents per ordinary share, amounting to a total of approximately RMB1,700,749,000 was approved by the Company's shareholders at the annual general meeting and was fully paid on 18 July 2024.

The board does not recommend the payment of any interim dividend for the six months ended 30 June 2024.

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent of RMB285,847,000 (2023: RMB255,461,000), and the weighted average number of ordinary shares of 1,171,810,382 (six months ended 30 June 2023: 1,170,059,826) in issue during the period, as adjusted to reflect the shares held for share award arrangement and shares repurchased during the period.

The calculation of diluted earnings per share for the six months ended 30 June 2024 did not assume the exercise of all dilutive potential ordinary shares arising from RSUs granted by the Company because the exercise price of these RSUs was higher than the average market price for shares for the period.

The calculation of the diluted earnings per share amount is based on the profit for the six months ended 30 June 2023 attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise of all dilutive potential ordinary shares arising from share options and RSUs granted by the Company.

7. 股息

於2024年5月27日，末期股息每股普通股人民幣41分及特別股息每股普通股人民幣99分，總額約人民幣1,700,749,000元獲本公司股東於股東週年大會上批准並於2024年7月18日獲悉數派付。

董事會不建議派付截至2024年6月30日止六個月的任何中期股息。

8. 母公司普通股持有人應佔每股盈利

每股基本盈利金額乃根據母公司普通股持有人應佔期內利潤人民幣285,847,000元（2023年：人民幣255,461,000元）及期內已發行普通股加權平均數1,171,810,382股（截至2023年6月30日止六個月：1,170,059,826股）計算，並經調整以反映就股份獎勵安排所持有的股份及於期內購回的股份。

截至2024年6月30日止六個月，每股攤薄盈利的計算並無假設本公司授予的受限制股份單位產生的所有攤薄潛在普通股獲行使，原因為該等受限制股份單位的行使價高於期內股份的平均市價。

每股攤薄盈利金額乃根據母公司普通股持有人應佔截至2023年6月30日止六個月利潤計算。計算中所用的普通股加權平均數為期內已發行普通股數目（用於計算每股基本盈利），並假設因本公司授出的購股權及受限制股份單位產生的所有攤薄潛在普通股視同獲行使後已無償發行的普通股加權平均數計算。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (continued)

The calculations of basic and diluted earnings per share are based on:

8. 母公司普通股持有人應佔每股盈利 (續)

每股基本及攤薄盈利的計算乃基於：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
<u>Earnings</u>	<u>盈利</u>		
Profit attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation	用於計算每股基本及攤薄盈利的母公司普通股持有人應佔利潤	285,847	255,461
		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核)	2023 2023年 (Unaudited) (未經審核)
<u>Shares</u>	<u>股份</u>		
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation	用於計算每股基本盈利的期內已發行普通股加權平均數	1,171,810,382	1,170,059,826
Effect of dilution-weighted average number of ordinary shares arising from share options and restricted share units	攤薄影響—因購股權及受限制股份單位產生的普通股加權平均數	-	5,312,991
Total	總計	1,171,810,382	1,175,372,817

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

9. PROPERTY, PLANT AND EQUIPMENT

9. 物業、廠房及設備

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Carrying amount at beginning of period/year	期初／年初賬面值	220,874	169,020
Additions	添置	33,433	81,381
Deconsolidation of a subsidiary	取消合併一間附屬公司	(14,576)	-
Depreciation provided during the period/year	於期內／年內計提折舊	(9,943)	(21,918)
Disposals	出售	(294)	(602)
Assets included in the disposal group held for sale	列入持作出售的出售組別資產	-	(7,010)
Exchange realignment	匯兌調整	1	3
Carrying amount at end of period/year	期末／年末賬面值	229,495	220,874

10. INVESTMENT IN AN ASSOCIATE

10. 於一間聯營公司的投資

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元
At 1 January 2024	於2024年1月1日	-
Arising from deconsolidation (note 17)	取消合併產生 (附註17)	347,344
Additional investment	額外投資	10,000
Share of losses	分佔虧損	(5,868)
At 30 June 2024	於2024年6月30日	351,476

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

10. INVESTMENT IN AN ASSOCIATE (continued)

Particulars of the Group's associate as at the reporting date are as follows:

Name 名稱	Place of incorporation/ registration and business 註冊成立/註冊及 營業地點	Nominal value of issued/ registered share capital 已發行/ 註冊股本面值	Percentage of ownership interest attributable to the Group 本集團應佔 所有權益百分比	Principal activities 主要活動
Hangzhou Weijing Medical Robot Co., Ltd. ("Weijing Medical")	PRC/Chinese Mainland	RMB1,486,989	37%	Research and development of medical instruments
杭州唯精醫療機器人有限公司 (「唯精醫療」)	中國/中國內地	人民幣1,486,989元		研發醫療器材

The Group's shareholdings in the associate comprise equity shares held through a wholly-owned subsidiary of the Company.

11. TRADE RECEIVABLES

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Trade receivables	貿易應收款項	220,768	229,614
Impairment	減值	(3,322)	(4,080)
		217,446	225,534

The Group's trading terms with its customers are mainly on credit. The credit period is generally one month, extending up to two to six months for certain customers. The Group seeks to maintain strict control over its outstanding receivables and overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancement over its trade receivable balances. Trade receivables are non-interest-bearing.

10. 於一間聯營公司的投資 (續)

本集團於報告日期的聯營公司詳情如下：

本集團於聯營公司的股權包括透過本公司全資附屬公司持有的股權。

11. 貿易應收款項

本集團與其客戶的貿易條款主要為信貸。信貸期一般為一個月，對若干客戶可延長最多兩至六個月。本集團致力嚴格監控未收回的應收款項，並由高級管理層定期覆核逾期結餘。鑒於以上所述及本集團的貿易應收款項涉及大量多元化的客戶，因此並不存在信貸風險高度集中的情況。本集團並無就其貿易應收款項結餘持有任何抵押品或採取其他信貸增強措施。貿易應收款項為免息。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

11. TRADE RECEIVABLES (continued)

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 3 months	3個月內	187,772	184,728
3 to 6 months	3至6個月	12,757	26,414
6 to 12 months	6至12個月	15,524	12,207
1 to 2 years	1至2年	1,378	2,144
Over 2 years	超過2年	15	41
Total	總計	217,446	225,534

12. PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Prepayments	預付款項	962	2,070
Other receivables	其他應收款項	1,902	3,727
Prepaid expenses	預付開支	5,950	3,914
Contribution receivable (note)	應收出資 (附註)	108,707	-
Total	總計	117,521	9,711

Note:

In May 2024, a director, certain key management personnel and an employee exercised a total of 16,860,000 shares at the subscription price of RMB6.45 per share, resulting in a total cash consideration of RMB108,707,000. The cash consideration is required to be fully settled no later than the fifth anniversary of the exercised date and bears an interest before its settlement. The interest rate was 1.8% per annum for the current period and will be adjusted annually.

11. 貿易應收款項 (續)

於報告期末，貿易應收款項 (扣除虧損撥備) 按發票日期劃分的賬齡分析如下：

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 3 months	3個月內	187,772	184,728
3 to 6 months	3至6個月	12,757	26,414
6 to 12 months	6至12個月	15,524	12,207
1 to 2 years	1至2年	1,378	2,144
Over 2 years	超過2年	15	41
Total	總計	217,446	225,534

12. 預付款項、其他應收款項及其他資產

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Prepayments	預付款項	962	2,070
Other receivables	其他應收款項	1,902	3,727
Prepaid expenses	預付開支	5,950	3,914
Contribution receivable (note)	應收出資 (附註)	108,707	-
Total	總計	117,521	9,711

附註：

於2024年5月，一名董事、若干關鍵管理人員及一名僱員按認購價每股人民幣6.45元行使合共16,860,000股股份，總現金代價為人民幣108,707,000元。現金代價須不遲於行使日期五週年悉數結算，且於結算前計息。本期間年利率為1.8%，並將每年進行調整。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

13. CASH AND CASH EQUIVALENTS

13. 現金及現金等價物

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Cash and bank balances	現金及銀行結餘	487,649	893,171
Time deposits	定期存款	2,280,064	1,783,417
Subtotal	小計	2,767,713	2,676,588
Less:	減：		
Non-current time deposits	非流動定期存款	(50,000)	-
Cash and cash equivalents	現金及現金等價物	2,717,713	2,676,588
Denominated in RMB	以人民幣計值	452,854	1,533,309
Denominated in US\$	以美元計值	2,110,610	1,135,716
Denominated in HK\$	以港元計值	151,768	6,677
Denominated in other currencies	以其他貨幣計值	2,481	886
Cash and cash equivalents	現金及現金等價物	2,717,713	2,676,588

The RMB is not freely convertible into other currencies. However, under Chinese Mainland's Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Time deposits are made for varying periods depending on the immediate cash requirements of the Group, and earn interest at the respective time deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default.

人民幣不能自由兌換為其他貨幣。然而，根據中國內地《外匯管理條例》及《結匯、售匯及付匯管理規定》，本集團獲准透過獲授權開展外匯業務的銀行將人民幣兌換為其他貨幣。

銀行現金根據每日銀行存款利率按浮動利率計息。視乎本集團的即時現金需求，定期存款的期限有所不同，並按各自的定期存款利率計息。銀行結餘乃存放於信譽良好且近期並無違約記錄的銀行。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

14. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 3 months	3個月內	24,671	27,130
3 to 6 months	3至6個月	612	1,517
6 to 12 months	6至12個月	919	3,708
Over 12 months	超過12個月	3,947	1,791
Total	總計	30,149	34,146

Trade payables are non-interest-bearing and are normally settled on 45-day terms.

15. OTHER PAYABLES AND ACCRUALS

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Contract liabilities	合約負債	5,240	2,142
Payroll payables	應付工資	11,878	23,683
Other payables	其他應付款項	35,151	25,428
Taxes other than income tax	所得稅以外的稅項	20,948	20,792
Accrued expenses	應計開支	4,006	10,039
Advance consideration for disposal of a subsidiary	出售一間附屬公司的預付代價	50,000	-
Contingent consideration payable (note)	應付或然代價 (附註)	118,000	-
Total	總計	245,223	82,084

14. 貿易應付款項

於報告期末，貿易應付款項按發票日期的賬齡分析如下：

	30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 3 months	24,671	27,130
3 to 6 months	612	1,517
6 to 12 months	919	3,708
Over 12 months	3,947	1,791
Total	30,149	34,146

貿易應付款項不計息，通常按45天的期限結算。

15. 其他應付款項及預提項目

	30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Contract liabilities	5,240	2,142
Payroll payables	11,878	23,683
Other payables	35,151	25,428
Taxes other than income tax	20,948	20,792
Accrued expenses	4,006	10,039
Advance consideration for disposal of a subsidiary	50,000	-
Contingent consideration payable (note)	118,000	-
Total	245,223	82,084

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

15. OTHER PAYABLES AND ACCRUALS (continued)

Note:

As part of the equity investment agreement between the Group and Weijing Medical, contingent consideration related to the capital injection to Weijing Medical is payable, which is dependent on the occurrence of milestone events, mainly including the achievement of medical device registration of Weijing Medical's products and completing a new round of financing. The contingent consideration is expected to be paid within one year as at 30 June 2024.

16. SHARE CAPITAL

15. 其他應付款項及預提項目 (續)

附註：

作為本集團與唯精醫療股本投資協議的一部分，本集團需支付與唯精醫療注資相關的或然代價，該筆或然代價乃取決於里程碑事件的發生，當中主要包括唯精醫療產品成功取得醫療器械註冊並完成新一輪融資。預期或然代價將於截至2024年6月30日止一年內支付。

16. 股本

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核)	31 December 2023 2023年 12月31日 (Audited) (經審核)
Authorised: 5,000,000,000 (2023: 5,000,000,000) ordinary shares of US\$0.00001 each US\$	法定： 5,000,000,000股 (2023年： 5,000,000,000股) 每股 0.00001美元的普通股 美元	50,000	50,000
Issued and fully paid: 1,214,821,000 (2023: 1,216,792,000) ordinary shares of US\$0.00001 each US\$ RMB	已發行及繳足： 1,214,821,000股 (2023年： 1,216,792,000股) 每股 0.00001美元的普通股 美元 人民幣	12,148 85,373	12,168 85,511

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

16. SHARE CAPITAL (continued)

A summary of movements in the Company's issued share capital, share premium, share held for share award arrangement and treasury shares is as follows:

		Notes 附註	Number of shares in issue 已發行股份數目	Share capital 股本 RMB'000 人民幣千元	Share premium account 股份溢價賬 RMB'000 人民幣千元	Share held for share award arrangement 就股份獎勵安排持有的股份 RMB'000 人民幣千元	Treasury shares 庫存股份 RMB'000 人民幣千元
At 1 January 2023 (audited)	於2023年1月1日 (經審核)		1,219,313,000	86	2,481,480	(3)	(5,495)
Shares repurchased	已購回股份	(a)	-	-	-	-	(16,580)
Shares cancelled	已註銷股份	(a)	(2,521,000)	-	(19,202)	-	19,202
At 31 December 2023 and 1 January 2024 (audited)	於2023年12月31日 及2024年1月1日 (經審核)		1,216,792,000	86	2,462,278	(3)	(2,873)
Dividends declared	已宣派股息	(b)	-	-	(651,680)	-	-
Exercise of share awards	行使股份獎勵	(c)	-	-	133,917	1	-
Shares repurchased	已購回股份	(d)	-	-	-	-	(30,805)
Shares cancelled	已註銷股份	(d)	(1,971,000)	(1)	(12,083)	-	12,084
At 30 June 2024 (unaudited)	於2024年6月30日 (未經審核)		1,214,821,000	85	1,932,432	(2)	(21,594)

A summary of movements in the Company's issued share capital, share premium, share held for share award arrangement and treasury shares is as follows:

- (a) The Company purchased 2,261,000 of its shares on the Stock Exchange at a total cash consideration of HK\$18,867,000 (equivalent to approximately RMB16,580,000), of which 1,780,500 shares with an amount equivalent to approximately RMB13,708,000 were cancelled during the year ended 31 December 2023. The remaining of 480,500 shares were cancelled on 31 January 2024.

16. 股本 (續)

本公司已發行股本、股份溢價、就股份獎勵安排持有的股份及庫存股份變動概述如下：

本公司已發行股本、股份溢價、就股份獎勵安排持有的股份及庫存股份變動概述如下：

- (a) 本公司於聯交所購買其2,261,000股股份，總現金代價為18,867,000港元（相當於約人民幣16,580,000元），其中1,780,500股股份（相當於約人民幣13,708,000元）已於截至2023年12月31日止年度註銷。餘下480,500股股份已於2024年1月31日註銷。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

16. SHARE CAPITAL (continued)

- (b) On 27 May 2024, the final dividend of RMB41 cents per ordinary share and a special dividend of RMB99 cents per ordinary share, amounting to a total of approximately RMB1,700,749,000 was approved by the Company's shareholders at the annual general meeting. The special dividend was paid partly out of the Company's share premium account of RMB651,680,000.
- (c) During the period, a total of 16,860,000 shares under the restricted share unit plan were exercised at the subscription price of RMB6.45 per share, resulting in the issue of 16,860,000 shares for a total cash consideration of RMB108,707,000. An amount of RMB25,210,000 was transferred from the share award reserve to share premium upon the exercise of restricted share units.
- (d) The Company purchased 5,509,500 of its shares on the Stock Exchange at a total cash consideration of HK\$33,846,000 (equivalent to approximately RMB30,805,000), of which 1,490,500 shares with an amount equivalent to approximately RMB9,210,000 were cancelled during the period ended 30 June 2024. The remaining of 4,019,000 shares were cancelled on 31 July 2024.

17. DECONSOLIDATION OF A SUBSIDIARY

On 20 March 2024, the shareholders of Weijing Medical approved certain amendments to the articles of association and the change in board composition of Weijing Medical. Upon the amendments becoming effective, the Group lost control of Weijing Medical and thus Weijing Medical ceased to be a subsidiary of the Group. As a result, the Group's retained interests in Weijing Medical was accounted for as an investment in an associate in the consolidated financial statements of the Group since then.

16. 股本 (續)

- (b) 於2024年5月27日，末期股息每股普通股人民幣41分及特別股息每股普通股人民幣99分，總額約人民幣1,700,749,000元獲本公司股東於股東週年大會上批准。部分特別股息人民幣651,680,000元已自本公司的股份溢價賬派付。
- (c) 期內，受限制股份單位計劃下的合共16,860,000股股份已獲行使，認購價為每股人民幣6.45元，因此發行16,860,000股股份，總現金代價為人民幣108,707,000元。於受限制股份單位獲行使後，人民幣25,210,000元已自股份獎勵儲備轉撥至股份溢價。
- (d) 本公司於聯交所購買其5,509,500股股份，總現金代價為33,846,000港元（相當於約人民幣30,805,000元），其中金額相當於約人民幣9,210,000元的1,490,500股股份已於截至2024年6月30日止期間註銷。餘下4,019,000股股份已於2024年7月31日註銷。

17. 取消合併一間附屬公司

於2024年3月20日，唯精醫療股東已批准唯精醫療組織章程細則若干修訂及董事會組成變動。修訂生效後，本集團失去對唯精醫療的控制權，故唯精醫療不再為本集團之附屬公司。因此，本集團於唯精醫療的保留權益自此於本集團的綜合財務報表中入賬列作於一間聯營公司的投資。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

17. DECONSOLIDATION OF A SUBSIDIARY (continued)

A summary of the effects of the deconsolidation of a subsidiary during the period ended 30 June 2024 was as follows:

17. 取消合併一間附屬公司 (續)

截至2024年6月30日止期間，取消合併一間附屬公司的影響概述如下：

		RMB'000 人民幣千元 Unaudited (未經審核)
Net assets disposed of:	所出售的資產淨值：	
Property, plant and equipment	物業、廠房及設備	14,576
Right-of-use assets	使用權資產	34,542
Intangible assets	無形資產	284,632
Cash and cash equivalents	現金及現金等價物	8,829
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	191,082
Inventories	存貨	16,533
Trade payables	貿易應付款項	(5,000)
Other payables and accruals	其他應付款項及預提項目	(4,321)
Lease liabilities	租賃負債	(38,048)
Deferred tax liabilities	遞延稅項負債	(66,020)
Goodwill	商譽	167,209
Non-controlling interests	非控股權益	(283,923)
		320,091
Gain on deconsolidation of a subsidiary	取消合併一間附屬公司的收益	27,253
		347,344*
Net outflow of cash and cash equivalents in respect of the disposal of a subsidiary	出售一間附屬公司的現金及現金等價物流出淨額	(8,829)

* The amount is the fair value of the Group's retained interest in Weijing Medical, as estimated with the assistance of an independent professional valuer.

* 此金額為本集團於獨立專業估值師協助下估計的唯精醫療保留權益的公允價值。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

18. COMMITMENTS

The Group had the following contractual commitments as at the end of the reporting period:

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Buildings	樓宇	35,681	45,708
Plant and machinery	機器及設備	1,032	84
Total	總計	36,713	45,792

19. RELATED PARTY TRANSACTIONS

Detail of the Group's principal related party is as follow:

Name	Relationship
Hangzhou Kangyin Investment Ltd. ("Kangyin Investment")	An entity controlled by a director
Weijing Medical	An associate

(a) The Group had the following transactions with related parties during the period:

(i) During the year ended 31 December 2023, a subsidiary of the Group entered into an lease agreement to rent office premises from Kangyin Investment for a period of three years commencing from 1 January 2023, with an annual rental fee of RMB1,200,000 for the first year, RMB1,320,000 for the second year and RMB1,452,000 for the third year. During the period, the Group paid RMB1,264,000 (2023:RMB1,200,000) of rental fee to Kangyin Investment.

(ii) During the period, the Group sold medical instruments to Weijing Medical of RMB75,000. The sales to the associate were made according to the published prices and conditions offered to the major customers of the Group.

18. 承擔

本集團於報告期末的合約承擔如下：

		30 June 2024 2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Buildings	樓宇	35,681	45,708
Plant and machinery	機器及設備	1,032	84
Total	總計	36,713	45,792

19. 關聯方交易

本集團主要關聯方的詳情如下：

名稱	關係
杭州康銀投資 管理有限公司 ("康銀投資")	董事控制的實體
唯精醫療	聯營公司

(a) 本集團於報告期內與關聯方的交易如下：

(i) 截至2023年12月31日止年度，本集團一間附屬公司訂立租賃協議，自2023年1月1日起為期三年向康銀投資租用辦公室物業，第一年租金為人民幣1,200,000元，第二年租金為人民幣1,320,000元，第三年租金為人民幣1,452,000元。期內，本集團向康銀投資支付租金人民幣1,264,000元（2023年：人民幣1,200,000元）。

(ii) 期內，本集團向唯精醫療出售醫療器材人民幣75,000元。向聯營公司銷售乃根據向本集團主要客戶提供的已公佈價格及條件進行。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

19. RELATED PARTY TRANSACTIONS (continued)

- (b) As at the end of the reporting period, the Group had outstanding balances with its related parties, as follows:

		30 June 2024 2024年 6月30日 RMB'000 (未經審核) (Unaudited) 人民幣千元	31 December 2023 2023年 12月31日 RMB'000 (經審核) (Audited) 人民幣千元
Contribution receivable from*:	來自以下各項的 應收出資*:		
A director	一名董事	26,597	-
Key management personnel	主要管理人員	76,436	-
		103,033	-
Contingent consideration payable to an associate**:	應付聯營公司的或然 代價**:		
Weijing Medical	唯精醫療	118,000	-

* The contribution receivable was related to receivables arising from the exercise of shares by a director and certain key management personnel, in a total of 15,980,000 shares at the subscription price of RMB6.45 per share, resulting in a total cash consideration of RMB103,033,000. The cash consideration is required to be fully settled no later than the fifth anniversary of the exercised date and bears an interest before its settlement. The interest rate was 1.8% per annum for the current period and will be adjusted annually. As at 30 June 2024, the outstanding balance is RMB103,033,000.

** The contingent consideration payable was related to the capital injection to Weijing Medical. Please refer to note 15 for further details.

The balances are non-trade in nature.

19. 關聯方交易 (續)

- (b) 於報告期末，本集團與關聯方之間的未償付結餘如下：

		30 June 2024 2024年 6月30日 RMB'000 (未經審核) (Unaudited) 人民幣千元	31 December 2023 2023年 12月31日 RMB'000 (經審核) (Audited) 人民幣千元
Contribution receivable from*:	來自以下各項的 應收出資*:		
A director	一名董事	26,597	-
Key management personnel	主要管理人員	76,436	-
		103,033	-
Contingent consideration payable to an associate**:	應付聯營公司的或然 代價**:		
Weijing Medical	唯精醫療	118,000	-

* 應收出資與應收一名董事及若干主要管理人員行使股份產生的應收款項有關，合共為15,980,000股，認購價為每股人民幣6.45元，因此總現金代價為人民幣103,033,000元。現金對價須不遲於行使日期第五週年悉數結付，並在結付前計息。本期間年利率為1.8%，並將每年作出調整。於2024年6月30日，未償付結餘為103,033,000元。

** 應付或然代價與注資唯精醫療有關。進一步詳情請參閱附註15。

該等結餘為非貿易性質。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

19. RELATED PARTY TRANSACTIONS (continued)

- (c) Compensation of key management personnel of the Group:

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Short term employee benefits	僱員短期福利	4,319	3,731
Pension scheme contributions	退休金計劃供款	128	203
Share-based payment expense	以股份為基礎的付款 開支	5,585	5,275
Total compensation paid to key management personnel	支付予主要管理人員的 薪酬總額	10,032	9,209

19. 關聯方交易 (續)

- (c) 本集團主要管理人員的薪酬：

20. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at 30 June 2024 and 31 December 2023 are as follows:

As at 30 June 2024 (unaudited)

Financial assets

		Financial assets at fair value through profit or loss 以公允價值計量且其變動計入當期損益的 金融資產 RMB'000 人民幣千元	Financial assets at amortised cost 按攤銷成本列賬的 金融資產 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
Trade receivables	貿易應收款項	-	217,446	217,446
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的 金融資產	-	110,609	110,609
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的 金融資產	202,834	-	202,834
Time deposits	定期存款	-	50,000	50,000
Cash and cash equivalents	現金及現金等價物	-	2,717,713	2,717,713
Total	總計	202,834	3,095,768	3,298,602

20. 按類別劃分的金融工具

於2024年6月30日及2023年12月31日，各類別金融工具的賬面值如下：

於2024年6月30日 (未經審核)

金融資產

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

20. FINANCIAL INSTRUMENTS BY CATEGORY (continued)

The carrying amounts of each of the categories of financial instruments as at 30 June 2024 and 31 December 2023 are as follows: (continued)

As at 30 June 2024 (unaudited)

Financial liabilities

Trade payables	貿易應付款項	
Dividend payable	應付股息	
Financial liabilities included in other payables and accruals	計入其他應付款項及預提項目的金融負債	
Total	總計	

As at 31 December 2023 (audited)

Financial assets

Trade receivables	貿易應收款項	
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產	
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產	
Cash and cash equivalents	現金及現金等價物	
Total	總計	

20. 按類別劃分的金融工具 (續)

於2024年6月30日及2023年12月31日，各類別金融工具的賬面值如下：
(續)

於2024年6月30日 (未經審核)

金融負債

Financial liabilities at fair value through profit or loss 以公允價值計量且其變動計入當期損益的金融負債 RMB'000 人民幣千元	Financial liabilities at amortised cost 按攤銷成本列賬的金融負債 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
-	30,149	30,149
-	1,663,886	1,663,886
118,000	39,157	157,157
118,000	1,733,192	1,851,192

於2023年12月31日 (經審核)

金融資產

Financial assets at fair value through profit or loss 以公允價值計量且其變動計入當期損益的金融資產 RMB'000 人民幣千元	Financial assets at amortised cost 按攤銷成本列賬的金融資產 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
-	225,534	225,534
-	3,727	3,727
153,167	-	153,167
-	2,676,588	2,676,588
153,167	2,905,849	3,059,016

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

20. FINANCIAL INSTRUMENTS BY CATEGORY (continued)

The carrying amounts of each of the categories of financial instruments as at 30 June 2024 and 31 December 2023 are as follows: (continued)

As at 31 December 2023 (audited)

Financial liabilities

Trade payables	貿易應付款項	34,146
Financial liabilities included in other payables and accruals	計入其他應付款項及預提項目的金融負債	35,467
Total	總計	69,613

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, trade receivables, financial assets included in prepayments, other receivables and other assets, trade payables, lease liabilities and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short-term maturities of these instruments.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The Group invests in unlisted investments, which represent wealth management products issued by banks in Chinese Mainland. The Group has estimated the fair value of these unlisted investments by using a discounted cash flow valuation model based on the market interest rates of instruments with similar terms and risks.

20. 按類別劃分的金融工具 (續)

於2024年6月30日及2023年12月31日，各類別金融工具的賬面值如下：
(續)

於2023年12月31日 (經審核)

金融負債

Financial liabilities at amortised cost
按攤銷成本列賬的金融負債
RMB'000
人民幣千元

21. 金融工具的公允價值及公允價值層級

管理層經評估後認為，現金及現金等價物、貿易應收款項、計入預付款項、其他應收款項及其他資產的金融資產、貿易應付款項、租賃負債及計入其他應付款項及預提項目的金融負債的公允價值與其賬面值大致相若，主要是由於該等工具的到期時間短。

金融資產及負債的公允價值按自願雙方在當前交易 (強迫或清盤出售除外) 中交換工具可得的金額入賬。

本集團投資於非上市投資，即中國內地銀行發行的理財產品。本集團已根據具有類似條款及風險的工具的市場利率，採用折現現金流估值模型估計該等非上市投資的公允價值。

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

The Group has used valuation techniques such as market method and the discounted cash flow method for the valuation of the unlisted equity investments and contingent consideration payables at the end of period. These valuations require the Group to make estimates about risk-free rate, discount rate, discount for lack of marketability, probability of initial public offering and market value versus research and development cost, and hence, they are subject to uncertainty. The Group classifies the fair value of these instruments as Level 2 and Level 3.

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2024 (unaudited)

	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
	活躍市場報價 (第一級)	重大可觀察輸入值 (第二級)	重大不可觀察輸入值 (第三級)	總計
	RMB'000	RMB'000	RMB'000	RMB'000
	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Financial assets at fair value through profit or loss	-	61,116	141,718	202,834

以公允價值計量且其變動計入當期損益的金融資產

21. 金融工具的公允價值及公允價值層級 (續)

本集團採用市場法、現金流量折現法等估價技術估計期末非上市股權投資及應付或然代價的價值。該等估值需要本集團對無風險利率、折現率、缺乏適銷性折讓、首次公開發行的可能性以及市場價值與研發成本進行估計，因此存在不確定性。本集團將該等工具的公允價值分類為第二級和第三級。

公允價值層級

下表闡述本集團金融工具的公允價值計量層級：

按公允價值計量的資產：

於2024年6月30日 (未經審核)

Fair value measurement using
公允價值採用以下方式計量

	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
	活躍市場報價 (第一級)	重大可觀察輸入值 (第二級)	重大不可觀察輸入值 (第三級)	總計
	RMB'000	RMB'000	RMB'000	RMB'000
	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Financial assets at fair value through profit or loss	-	61,116	141,718	202,834

Notes to the Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

As at 31 December 2023 (audited)

		Fair value measurement using 公允價值採用以下方式計量			
	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)		Total
	活躍市場報價 (第一級)	重大可觀察輸入值 (第二級)	重大不可觀察輸入值 (第三級)		總計
	RMB'000	RMB'000	RMB'000		RMB'000
	人民幣千元	人民幣千元	人民幣千元		人民幣千元
Financial assets at fair value through profit or loss		以公允價值計量且其變動計入當期損益的金融資產			
	-	11,449	141,718		153,167

Liabilities measured at fair value:

As at 30 June 2024 (unaudited)

		Fair value measurement using 公允價值採用以下方式計量			
	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)		Total
	活躍市場報價 (第一級)	重大可觀察輸入值 (第二級)	重大不可觀察輸入值 (第三級)		總計
	RMB'000	RMB'000	RMB'000		RMB'000
	人民幣千元	人民幣千元	人民幣千元		人民幣千元
Contingent consideration payable		應付或然負債			
	-	-	118,000		118,000

The Group did not have any financial liabilities measured at fair value as at 31 December 2023.

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (six months ended 30 June 2023: Nil).

21. 金融工具的公允價值及公允價值層級 (續)

下表闡述本集團金融工具的公允價值計量層級：

於2023年12月31日 (經審核)

		Fair value measurement using 公允價值採用以下方式計量			
	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)		Total
	活躍市場報價 (第一級)	重大可觀察輸入值 (第二級)	重大不可觀察輸入值 (第三級)		總計
	RMB'000	RMB'000	RMB'000		RMB'000
	人民幣千元	人民幣千元	人民幣千元		人民幣千元
Financial assets at fair value through profit or loss		以公允價值計量且其變動計入當期損益的金融資產			
	-	11,449	141,718		153,167

按公允價值計量的負債：

於2024年6月30日 (未經審核)

		Fair value measurement using 公允價值採用以下方式計量			
	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)		Total
	活躍市場報價 (第一級)	重大可觀察輸入值 (第二級)	重大不可觀察輸入值 (第三級)		總計
	RMB'000	RMB'000	RMB'000		RMB'000
	人民幣千元	人民幣千元	人民幣千元		人民幣千元
Contingent consideration payable		應付或然負債			
	-	-	118,000		118,000

於2023年12月31日，本集團並無任何以公允價值計量的金融負債。

於期內，金融資產及金融負債概無在第一級與第二級公允價值計量之間轉移，亦無轉入或轉出第三級 (截至2023年6月30日止六個月：無)。

Definitions

釋義

“Audit Committee” 「審核委員會」	指	the audit committee of the Board 董事會審核委員會
“Board” 「董事會」	指	the board of directors of the Company 本公司董事會
“CG Code” 「《企業管治守則》」	指	Corporate Governance Code and Corporate Governance Report 《企業管治守則》及《企業管治報告》
“China” or “PRC” 「中國」或「中國內地」	指	People’s Republic of China, excluding, for the purposes of this report and for geographical reference only and except where the context requires otherwise, Hong Kong, Macau and Taiwan 中華人民共和國，除文義另有所指外，就本報告及僅就地域參考而言，不包括香港、澳門及台灣
“Company” 「本公司」	指	Kangji Medical Holdings Limited (康基医疗控股有限公司), a company incorporated under the laws of the Cayman Islands with limited liability on February 12, 2020, and, except where the context otherwise requires, all of its subsidiaries 康基医疗控股有限公司，於2020年2月12日根據開曼群島法律註冊成立的有限公司，及(除文義另有所指外)其全部附屬公司
“Director(s)” 「董事」	指	the directors of the Company, including all executive, non-executive and independent non-executive directors 本公司董事，包括所有執行董事、非執行董事及獨立非執行董事
“Global Offering” 「全球發售」	指	the Hong Kong public offering and the international offering of the Company 本公司香港公開發售及國際發售
“Group” 「本集團」	指	the Company and all of its subsidiaries or, where the context so requires, in respect of the period before the Company became the holding company of its present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be) 本公司及其所有附屬公司，或如文義所指，於本公司成為其現有附屬公司的控股公司之前的期間，則指該等附屬公司或其前身公司(視情況而定)經營的業務
“Hangzhou Kangji” 「杭州康基」	指	Hangzhou Kangji Medical Instrument Ltd. (杭州康基醫療器械有限公司), a limited liability company established in the PRC on August 24, 2004 杭州康基醫療器械有限公司，一家於2004年8月24日在中國成立的有限責任公司
“HK\$” or “HKD” 「港元」	指	Hong Kong dollars, the lawful currency of Hong Kong 香港法定貨幣港元

Definitions

釋義

“HKFRS” 「《香港財務報告準則》」	指	Hong Kong Financial Reporting Standards 《香港財務報告準則》
“Hong Kong” 「香港」	指	the Hong Kong Special Administrative Region of the PRC 中國香港特別行政區
“IPO” 「首次公開發售」	指	initial public offering 首次公開發售
“Kangji Hong Kong” 「康基香港」	指	Kangji Medical (Hong Kong) Limited, a wholly-owned subsidiary of the Company established under the laws of Hong Kong 康基醫療(香港)有限公司，根據香港法律成立，為本公司的全資附屬公司
“Listing” 「上市」	指	the listing of the Shares on the Main Board of the Stock Exchange on June 29, 2020 股份於2020年6月29日於聯交所主板上市
“Listing Date” 「上市日期」	指	June 29, 2020, being the date on which dealings in the Shares first commenced on the Main Board 2020年6月29日，即股份首次於主板開始買賣的日期
“Listing Rules” 「《上市規則》」	指	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time 《香港聯合交易所有限公司證券上市規則》(經不時修訂或補充)
“Main Board” 「主板」	指	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Stock Exchange. For the avoidance of doubt, the Main Board excludes the Growth Enterprise Market of the Stock Exchange 由聯交所營運的證券交易所(不包括期權市場)，獨立於聯交所GEM，並與其並行運作。為免生疑問，主板不包括聯交所GEM
“Model Code” 「《標準守則》」	指	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules 《上市規則》附錄C3所載《上市發行人董事進行證券交易的標準守則》
“ODM” 「ODM」	指	original design manufacture 原設計製造
“Pre-IPO Share Option Plan” 「首次公開發售前購股權計劃」	指	the employees’ share incentive plan of the Company as adopted on May 6, 2020. 於2020年5月6日採納的本公司僱員股份獎勵計劃
“Prospectus” 「招股章程」	指	the Company’s prospectus dated June 16, 2020 本公司日期為2020年6月16日的招股章程

Definitions

釋義

“R&D” 「研發」	指	research and development 研究及開發
“RMB” 「人民幣」	指	the lawful currency of the PRC 中國的法定貨幣
“Reporting Period” 「報告期」	指	the six-month period from January 1, 2024 to June 30, 2024 2024年1月1日至2024年6月30日六個月期間
“RSU(s)” 「受限制股份單位」	指	restricted share unit(s) 受限制股份單位
“RSU Plan” 「受限制股份單位計劃」	指	the restricted share unit plan of the Company as adopted on May 6, 2020 本公司於2020年5月6日採納的受限制股份單位計劃
“SFO” 「《證券及期貨條例》」	指	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time 香港法例第571章《證券及期貨條例》，經不時修訂、補充或以其他方式修改
“Share(s)” 「股份」	指	ordinary shares in the share capital of the Company of US\$0.00001 each 本公司股本中每股面值0.00001美元的普通股
“Shareholder(s)” 「股東」	指	holder(s) of the Share(s) 股份持有人
“Stock Exchange” 「聯交所」	指	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchange and Clearing Limited 香港聯合交易所有限公司，為香港交易及結算所有限公司的全資附屬公司
“Substantial Shareholder(s)” 「主要股東」	指	has the meaning ascribed to it under the Listing Rules 具有《上市規則》賦予該詞的涵義
“U.S.” or “United States” 「美國」	指	the United States of America, its territories, its possessions and all areas subject to its jurisdiction 美利堅合眾國，其國土、屬地及受其司法管轄的所有地區
“USD” or “US\$” 「美元」	指	the lawful currency of the United States of America 美利堅合眾國法定貨幣
“VBP” 「集採」	指	volume-based procurement 集中帶量採購
“Weijing Medical” 「唯精醫療」	指	Hangzhou Weijing Medical Robot Co., Ltd. (杭州唯精醫療機器人有限公司), a limited liability company established in the PRC on December 28, 2021 杭州唯精醫療機器人有限公司，一家於2021年12月28日在中國成立的有限責任公司



混合產品
紙張 | 支持負責任的林業
Paper | Supporting responsible forestry
FSC® C004888